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Clear cell renal cell carcinoma (ccRCC) is characterized by an 
increased expression of the hypoxia inducible factors (HIF) due to VHL gene 
mutations. Targets of HIF, namely hexokinase II, lactate dehydrogenase 5 and 
pyruvate dehydrogenase (PDH) kinase 1 (PDHK1) are higher than patient-
matched normal tissues. PDHK1 phosphorylates and inhibits PDH whose 
enzymatic activity was negligible, depriving the TCA cycle of acetyl CoA.  
Lower expression of transcription factors (mtTFA, PGC-1α and NRF1) 
involved in mitochondrial biogenesis lead to the attenuated expressions and 
activities of the respiratory complexes, oxidative phosphorylation (OXPHOS) 
was therefore predicted to be compromised. However, we found that the 
biosynthesis of ATP, induction of mitochondrial membrane potential (MMP) 
and oxygen flux were measurable from the oxidation of conventional 
respiratory substrates in mitochondria isolated from ccRCC tumor tissues, 
demonstrating their “potential” for OXPHOS.  Interestingly, a consistently 
higher basal MMP was observed in tumor which could be due to the loss of 
UCP2. In addition, the ability of metabolizing the glutamine-derived 
substrates suggested the addiction of ccRCC tumor towards glutaminolysis 
due to a disconnection between glycolysis and the TCA cycle. Taken together, 
this study revealed the OXPHOS capacity of mitochondria isolated from 
ccRCC despite its glycolytic phenotype and suggested plausible mechanisms 
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CHAPTER 1 GENERAL INTRODUCTION AND AIMS OF STUDY 
1.1 The kidneys 
The kidneys are bean-shaped organs located at the rear of the abdominal 
cavity with one on each side of the vertebral column. The main function of 
kidneys is to filter waste products and excess fluid out of the blood in the form of 
urine which is eventually diverted into the urinary bladder. In the process of 
producing urine, wastes such as urea and ammonium are excreted whereas 
glucose, amino acids and a certain volume of water were reabsorbed.  
Besides their essential role in urinary system, kidneys are also responsible for 
regulation of electrolytes including sodium (Na+), chloride (Cl-), calcium (Ca2+), 
potassium (K+), magnesium (Mg2+) and hydrogen phosphate (HPO42-); 
maintenance of acid-base balance by reabsorption of bicarbonate and excretion of 
hydrogen ions; regulation of blood pressure via maintaining the water and salt 
balance; production of hormones (calcitriol and erythropoietin) and enzyme 
(renin). Calcitriol is the activated form of vitamin D and it is also important for 
the intestinal reabsorption of calcium and renal reabsorption of phosphate. 
Erythropoietin stimulates erythropoiesis in the bone marrow under hypoxic 
condition and renin, on the other hand, regulates the aldosterone level via the 
renin-angiotensin-aldosterone system. 
1.2 Renal cell carcinoma (RCC) 
Renal cell carcinoma (RCC) is a type of kidney cancer that the cancer 
cells form in the renal tubules in contrast to those that involve renal pelvis. RCC 
accounts for 3% of adult cancers and about 90% of all renal malignancies (Jemal 
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et al., 2010). The most recent estimation by the American Cancer Society states 
that 63920 new cases of kidney cancer and renal pelvis cancer are expected to 
occur and lead to 13860 deaths in the United States in 2014 (Siegel et al., 2014).  
RCC is a heterogeneous disease with histological variants of different 
clinical course, gene mutation and response to therapy. According to World 
Health Organization (WHO) classification, RCC is categorized into different 
subtypes based on morphology, namely clear cell, papillary, chromophobe, 
granular, spindle cell, cyst-associated, translocation carcinomas and collecting-
duct carcinomas (Eble J, 2004; Kovacs et al., 1997). Of these, clear cell renal cell 
carcinoma (ccRCC) is the most prevalent form, accounting for 75% followed by 
papillary 10%, chromophobe 5% and undifferentiated represent approximately 10% 
of cases.  ccRCC is named according to the typical presentation of clear 
cytoplasm due to intracellular lipid accumulation as depicted in Fig. 1.2. 
 
Fig. 1.2 Macroscopic appearance of clear cell RCC with the tumor area 
appears golden due to intracellular lipid accumulation. Abbreviations: C, 
renal cortex; P, renal pelvis; T, tumor. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Urology, 8, Valera VA and Merino MJ, 
Misdiagnosis of clear cell renal cell carcinoma, page 324, copyright 2011. 




 The incidence rates for RCC are highest in Europe and North America and 
lowest in Asia and Africa. RCC occurs more often in men as compared to women 
with ratio of 1.5:1 (Landis et al., 1999). Higher rates are also reported for urban in 
contrast to rural populations and black compared with white Americans (Decastro 
and McKiernan, 2008; McLaughlin et al., 2006; Pascual and Borque, 2008). RCC 
is a tumor of adults with the highest incidence reported in the fifth decade of life; 
about 80% of all RCC patients are between 40 to 69 year old (Pascual and Borque, 
2008). However, there were patients that were diagnosed with RCC at younger 
age of less than 40 or 14-18 years old in rare cases (Bruder et al., 2004; Taccoen 
et al., 2007). 
1.2.2 Etiology 
The exact cause of RCC is poorly understood but there are several risk 
factors that are associated with the development of RCC and tobacco smoking is 
one of them. Outcome from a meta-analysis demonstrated that people who smoke 
had higher risk for renal cancer than those who never smoke (Ferlay et al., 2007). 
Workers in industries who were exposed to toxic substances such as cadmium, 
coke ovens, steel, gasoline/petroleum (Boffetta et al., 2001; Mandel et al., 1995), 
trichloroethylene (TCE) (Bruning et al., 2003; Lungberg BC, 2011) and pesticides 
(Karami et al., 2008) had an increased risk for RCC. RCC is also associated with 
excess body weight as shown by the meta-analysis of prospective studies by 
Chow et al (Chow et al., 1999) in which the risk was increased by 1.24 in men 
and 1.34 in women per 5kg/m2 increase in body mass index. Dietary habit of fruit 
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and vegetable consumption was shown to have an inverse association with the 
incidence of RCC (29) but the correlation was not observed in two other studies 
(George et al., 2009; Weikert et al., 2006). In addition, alcohol intake has been 
shown to have an inverse association with risk of renal cell cancer (Lee et al., 
2006; Setiawan et al., 2007). 
1.2.3 Genetics 
Most cases of RCC are sporadic; however, with the several hereditary 
kidney cancer syndromes come to light, genes implicated in familial renal cancers 
have been identified.  
1.2.3.1 VHL 
Most of the RCC patients harbor the mutation in their von Hippel-Lindau 
(VHL) gene. It was first found in 1993 that RCC is associated with the 
chromosomal loss of VHL gene on chromosome 3p25-26 (Latif et al., 1993). The 
VHL protein is a tumor suppressor which together with elongin B, elongin C and 
cullin 2 (Kibel et al., 1995), form a complex that targets the hypoxia inducible 
factors (HIFs) for ubiquitination followed by proteasomal degradation (Iliopoulos 
et al., 1996; Maxwell et al., 1999). 
HIFs are basic helix-loop-helix transcription factors which regulate the 
expression for downstream genes in response to oxygen deprivation. Targets of 
HIFs such as vascular endothelial growth factor (VEGF), platelet-derived growth 
factor and glucose transporter 1 (Pfaffenroth and Linehan, 2008) are important 
genes implicated in angiogenesis, energy metabolism, erythropoiesis, cell 
proliferation and survival, pH regulation, proteolysis and apoptosis. 
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During normoxia, HIF-α is hydroxylated by HIF prolyl hydroxylase (PHD) 
at the critical proline residues which facilitate the binding site of VHL protein and 
subsequent proteolysis by the E3 ubiquitin ligase complex. Molecular oxygen, 2-
oxoglutarate, ascorbate and Fe2+ are required in this process. In contrast, PHD 
cannot hydroxylate HIF-α under hypoxic conditions or when VHL gene is mutated, 
no binding of pVHL leads to the accumulation of HIF-α. The steps involved in 
HIF1α by PHD are depicted in Fig. 1.2.3.1. There is considerable amount of 
overlap between the genes that are transcriptionally regulated by HIF-1α and HIF-
2α but the later was reported to be the crucial HIF for tumorigenesis in clear cell 
kidney cancer (Kondo et al., 2002). 
 
Fig. 1.2.3.1 Regulation of HIF1α by proline hydroxylation. Veronica AC and 
Margaret, Targeting the molecular basis for tumor hypoxia, Expect Reviews in 
Molecular Medicine, 7, page 5, 2005, reproduced with permission from 




The proto-oncogene mesenchymal-epithelial transition (MET) encodes a 
tyrosine kinase membrane receptor (Finley et al., 2011) for the binding of 
hepatocyte growth factor (HGF) which plays a role in mitogenesis, 
morphogenesis and motogenesis (Peruzzi and Bottaro, 2006). Gain-of-function 
mutations in the tyrosine kinase domain of MET result in consecutive activation 
of the receptor and multiple tumorigenic processes which have been reported in 
the germline of affected patients as well as in a subset of sporadic type 1 papillary 
kidney cancers (Schmidt et al., 1997; Schmidt et al., 1999).  
1.2.3.3 TSC1-TSC2 
Germline mutations in the tuberous sclerosis genes (TSC1 and TSC2) are 
implicated with the development of pulmonary lymphangiomyomatosis, 
cutaneous angiofibromas and renal tumors (Faivre et al., 2006). Hamartin and 
tuberin, encoded by TSC1 and TSC2 form a heterodimer that activates Rheb (a 
Ras family GTPase) which in turn inhibit mammalian target of rapamycin (mTOR) 
activity.  Lack of mTOR inhibition by TSC1-TSC results in an increased 
phosphorylation of 4E-BP1, p70S6 kinase, S6 ribosomal protein and thus causes 
higher protein synthesis.  
1.2.3.4 FLCN 
The loss-of-function mutations in the folliculin gene (FLCN) have been 
identified in patients with Birt-Hogg-Dubé syndrome (Schmidt et al., 2001) and 
they are at higher risk to develop benign cutaneous tumors (fibrofolliculomas) , 
pulmonary cysts (Birt et al., 1977) and chromophobe kidney tumors (Pavlovich et 
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al., 2005). Complex of folliculin with its interacting proteins 1 and 2 (FNIP1 and 
FNIP2) binds to ɣ-subunit of AMPK and regulates AMPK-mTOR signaling. The 
function of protein folliculin is not fully understood (Finley et al., 2011) but its 
inactivation leads to polycystic kidney degeneration and renal tumors in mouse 
models (Baba et al., 2006; Schmidt et al., 2001). An association between FLCN 
function and mTORC1 activity during renal tumorigenesis was also suggested 
(Baba et al., 2006; Chen et al., 2008; Hartman et al., 2009).  
1.2.3.5 FH  
FH encodes mitochondrial fumarate hydratase (FH) and its mutation is 
responsible for the development of hereditary leiomyomatosis renal cell 
carcinoma (HLRCC) (Tomlinson et al., 2002). Inhibition of FH leads to the 
accumulation of fumarate which inhibits the activity of PHD and resulting in 
upregulation of HIF (Isaacs et al., 2005). Glucose dependency (Sudarshan et al., 
2009; Yang et al., 2010) and impaired oxidative phosphorylation (OXPHOS) (Xie 
et al., 2009; Yang et al., 2010) are observed in FH-deficient kidney cancer cell 
lines.  
1.2.3.6 SDH  
Germline mutations in the three succinate dehydrogenase genes (SDHB, 
SDHC and SDHD) have been associated with familial pheochromocytoma and 
familial paraganglioma (Baysal et al., 2000; Vanharanta et al., 2004). Similar to 
FH, loss of SDH and the accumulation of succinate also result in pseudohypoxia 
and the stabilization of HIF (Isaacs et al., 2005). 
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1.2.4 Current treatments 
Nephrectomy, either partial or radical is the primary and most effective 
treatment known for localized renal cell carcinoma (Robson et al., 1969). For 
patients with metastatic tumor, surgical treatment is given as palliative care in 
addition to the standard regimens involving immunomodulatory agents and 
molecular-targeted therapy. Cytokine immunotherapy with interleukin-2 was 
shown to increase the median survival rate from 10 months to 34 months in 20% 
of patients with metastatic ccRCC. Tyrosine kinase inhibitors (sunitinib, sorafenib) 
that target the angiogenesis pathway and mTOR inhibitor (temsirolimus) which 
induces cell cycle arrest have been approved for the treatment of RCC. A 
response rate of 31% towards sunitinib observed in patients with advanced RCC 
assures the effectiveness of gene-targeting therapy and researchers are focusing 
on identifying more agents for targeted approaches including those contributing to 
the metabolic defect in RCC (Linehan et al., 2010; Turcotte et al., 2008). 
1.3 Energy metabolism in cells 
Cells require energy for their cellular activities such as cell growth, 
movement, transport and synthesis of macromolecules. The energy is derived 
from the oxidation of carbohydrate, fat or protein and is captured in the high-
energy phosphate bonds of adenosine triphosphate (ATP). The energy currency, 
ATP can then be used for energy-requiring reactions. The two major pathways 




1.3.1 Glucose metabolism 
Glucose is the six-carbon sugar that serves as the primary source of energy. 
It is converted into two molecules of three-carbon product, pyruvate by a 
metabolic pathway known as glycolysis. Energy released during this process is 
used to form adenosine triphosphate (ATP) and reduced nicotinamide adenine 
dinucleotide (NADH). Glycolysis comprises of ten enzyme-catalyzed reactions 
that take place in the cytoplasm (Fig. 1.3.1a).  
 
Fig. 1.3.1a Glycolysis. Reproduced from Circulation Research, 77, Xu KY et al, 
Functional coupling between glycolysis and sarcoplasmic reticulum Ca2 
Transport, Figure 1, 1995, with permission from Wolters Kluwer Health (License 
Number: 3445740299155).  
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Under anaerobic conditions, pyruvate is reduced to lactate by lactate 
dehydrogenase A (LDH-A) in the cytoplasm and lactate is exported from the cells 
via monocarboxylate transporters (MCTs). In the presence of oxygen, the end 
product, pyruvate enters the mitochondria and is oxidized to acetyl CoA by the 
action of pyruvate dehydrogenase (PDH). Other than pyruvate, acetyl CoA can 
also be generated by the oxidation of fatty acids and ketogenic amino acids. 
Acetyl CoA together with oxaloacetate initiate the tricarboxylic acid (TCA) cycle 
and give rise to the reducing equivalents, NADH and reduced flavin adenine 
dinucleotide (FADH2) which are ultimately channeled into electron transport 
chain (ETC) and ATP generation via oxidative phosphorylation (OXPHOS). 
OXPHOS is carried out by the five respiratory complexes found on the 
inner mitochondrial membrane (IMM). NADH and FADH2 from the TCA cycle 
are oxidized by Complex I (NADH-coenzyme Q oxidoreductase) and II 
(Succinate-Q oxidoreductase) respectively and the electrons-carried by them are 
transferred sequentially to the coenzyme Q (also known as ubiquinone), complex 
III (Q-cytochrome c oxidoreductase), cytochrome c and end at complex IV 
(cytochrome c oxidase) where oxygen is reduced to water. As the electrons pass 
through the chain, protons are pumped from the matrix into the intermembrane 
space, creating potential energy in the form of a pH gradient and an electrical 
potential across IMM. Protons return to the matrix via the complex V and the 
energy released is used to form ATP from adenosine diphosphate (ADP). The 
oxidative process is normally coupled to phosphorylation of ADP and therefore 




Fig. 1.3.1b Schematic diagram of the respiratory complexes that involved in 
the transfer the electrons and formation of ATP occur in the oxidative 
phosphorylation (OXPHOS). Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Molecular Cell Biology, 9, Ow, YP et al, 
Cytochrome c: functions beyond respiration, page 535, copyright 2008. (License 
Number: 3445760329775). 
 
OXPHOS is a more efficient pathway in generating energy because only 
two moles of ATP per mole of glucose are produced by glycolysis as compared to 
36 moles of ATP from OXPHOS in which glucose is fully oxidized to carbon 
dioxide and water.  
1.3.2 Lipid metabolism 
Lipids are important storage for energy, fundamental constituents of cell 
membranes and precursor of steroid hormones. The breakdown of lipids starts 
with the hydrolysis of lipid in the cytoplasm and give rise to glycerol and fatty 
acids. Glycerol can be metabolized to dihydroxyacetone phosphate, an 
intermediate of glycolysis or converted to glucose-6-phosphate in 
gluconeogenesis. Fatty acids are processed in the mitochondria, yielding acetyl-
coA, NADH and FADH2 via a pathway called beta-oxidation.  The fatty acids are 
first converted to fatty acyl-CoA by the enzyme fatty acyl CoA dehydrogenase at 
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the expense of one ATP. It is followed by a stepwise oxidation whereby the fatty 
acids are degraded by two carbons at a time, generating acetyl CoA and a fatty 
acyl-CoA shorter by two carbons. One molecule each of NADH and FADH2 
formed per round of oxidation are directed towards electron transport chain 
whereas the acetyl-coA enters the citric acid cycle. 
Total of 130 ATPs (21 from 7 NADH; 14 from FADH2; 96 from acetyl CoA 
and minus one used in the first step) can be produced per molecule of a 16-carbon 
fatty acid via beta- oxidation. By comparing the molecular mass of a saturated 16-
carbon fatty acid which is 256 and that of glucose which is 180, fatty acids have 
2.5 times higher yield of ATP per gram which explain why lipids are better 




1.4 Aims of study 
 This study aims to gain insights into the metabolic signature of clear cell 
renal cell carcinoma (ccRCC) when compared to the patient-matched normal 
tissue. Particulars of patients and clinical data on specimens collected were listed 
in Table 1.  Understanding of these bioenergetic differences would provide clues 
toward the development of potential therapeutic strategy for ccRCC.  
 Chapter 2 described work that confirmed the glycolytic phenotype of 
ccRCC with altered protein expressions of HIFs’ targets. This was accompanied 
with reduced protein levels of mitochondrial respiratory complexes and 
transcription factors responsible for mitochondrial biogenesis. These observations 
indicate that ccRCC depends greater on glycolysis than oxidative phosphorylation 
(OXPHOS) which believed to be impaired in cancer cells as suggested by 
Warburg.  
 Chapter 3 addressed the controversy of respiratory injury in cancer cells 
by examining the mitochondrial functions using intact mitochondria isolated from 
ccRCC tumor and normal tissue. Here the OXPHOS capacity from the aspects of 
ATP biosynthesis, oxygen consumption and mitochondrial membrane potential 
was examined. In addition, production of reactive oxygen species (ROS) will also 
be described. 
 As results from Chapter 4 suggested a higher basal mitochondrial 
membrane potential (MMP) in the ccRCC, role of uncoupling proteins (UCPs), 
ADP and respiratory substrates in maintaining the higher MMP was examined. 
786-O cells with UCP2 overexpression were assessed for the change in their 
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MMP. The ability of mitochondria isolated from ccRCC tumor in utilizing 
glutamine and its-derived substrates for synthesizing ATP and energization of 
















1 M 493 2.5 x 1.7 x 1.5 ccRCC 3/4 
No evidence 
of invasion 




3 F 417 10 x 6 x 4 ccRCC 1 Invasion not identified 













clear cell type 
3 Malignant 






7 M 686.0 9.0 x 7.5 x 7.0 
Renal cell 
carcinoma, 
clear cell type 
4 Malignant 
















10 M 674.0 7.2 x 6.2 x 5.0 
Renal cell 
carcinoma, 
clear cell type, 

























































17 NP 575.0 10.0 x 9.0 
x 4.5 
Conventional 





18 NP 370.0 9.5 x 8.5 x 7.5 
Conventional 





Table 1. Particulars of patients and classification of tumors. NP: Information not 
provided. 
 
(a) Tumor grossly encapsulated and extends beyond the confines of kidney; 





 Tumor extends into major vein, pT3a, hilar vascular margin with intraluminal 
tumor thrombus, without tumor invasion into vessel wall, Ureteric and perinephric 
resection margins not involved by tumor, one hilar lymph node with no evidence 
of malignancy (0/1). Para-aortic lymph node: One lymph node with no evidence 
of malignancy (0/1), Aorto-caval lymph nodes: Two lymph nodes with no 
evidence of malignancy (0/2). 
(c)
 Tumor has invaded into the perirenal fat and renal sinus fat, tumor seen grossly 
and microscopically in the large veins, lymphovascular invasion is present, tumor 
does not invade the pericolic fat or bowel wall. Twenty-two pericolic lymph 
nodes identified with no evidence of metastatic carcinoma (0/22). Resection 





CHAPTER 2 WARBURG EFFECT IN CLEAR CELL RENAL CELL 
CARCINOMA (CCRCC) 
2.1 Introduction 
2.1.1 Warburg effect 
 Normal differentiating cells rely mainly on oxidative phosphorylation for 
the production of energy required for cellular functions and processes. In contrast, 
cancer and proliferating cells convert glucose into lactate even in the presence of 
oxygen, a phenomenon known as “aerobic glycolysis” or the “Warburg effect”. 
The high rates of glucose uptake and lactic production in cancer cells was first 
described by Otto Warburg in 1956 (Warburg, 1956b) and this finding facilitates 
the exploitation of 18F-deoxyglucose positron emission tomography scanning in 
detecting solid tumor (Ter-Pogossian et al., 1975). Besides cancer’s sweet tooth, 
Warburg and his colleagues found that oxygen consumption was lower in cancer 
cells as compared to normal tissue cells even when oxygen was ample (Koppenol 
et al., 2011) and the impairment in respiration was postulated to be the underlying 
cause (Warburg, 1956a). 
 Half a century has passed and majority of cancer types have been found to 
display the Warburg phenotype which enables the generation of building blocks 
from glycolytic intermediates to allow the rapid proliferation of cancer cells (Hsu 
and Sabatini, 2008). Many tumors are characterized by the elevated lactate and 
the resulted acidosis degrades the stroma that surrounds the non-neoplastic cells 
which eventually lead to increased invasiveness of the cancer. In addition, the 
Warburg effect is always associated with the enhanced expression of the 
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transcription factor hypoxia-inducible factor-1α (HIF-1α) that regulates more than 
100 genes including those involved in glucose metabolism, angiogenesis, 
vasomotor regulation, cell growth and apoptosis (Chowdhury et al., 2008).  
2.1.2 Hexokinase II (HKII) and lactate dehydrogenase isoenzyme V (LDH5) 
Glycolytic enzymes, hexokinase II (HKII) and lactate dehydrogenase 
isoenzyme V (LDH5) are known to be transcriptionally regulated by HIF-1α 
(Koukourakis et al., 2005; Mathupala et al., 2001; Semenza et al., 1994). 
Hexokinase (HK) is the glycolytic enzyme that catalyzes rate-limiting step in 
glycolysis in which glucose is phosphorylated to glucose-6-phosphate (G6P). 
There are four major isozymes of hexokinase, referred as Types I, II, III and IV. 
Type II hexokinase (HKII) is the major isozymes that is overexpressed in cancer 
cells especially in those highly malignant tumor whereby there is a >100-fold 
elevation in its expression. Most of the HKII is bound to the outer mitochondrial 
membrane via the interaction with a protein called porin or VDAC (Nakashima et 
al., 1986). This strategic location of HKII allows preferred access to 
mitochondrially generated ATP (Arora and Pedersen, 1988), reduces the 
enzyme’s sensitivity to product inhibition by glucose-6-phosphate (G-6-P) 
(Bustamante and Pedersen, 1977) and offers protection against proteolytic 
degradation (Rose and Warms, 1982). 
Under hypoxic condition, pyruvate produced by glycolysis is converted 
into lactate by the action of lactate dehydrogenase (LDH). This reaction is 
accompanied by the interconversion of NADH to NAD+ which is crucial in 
ensuring the regeneration of NAD+ for glycolysis and other metabolic activities. 
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Five LDH isozymes have been described and structurally they are tetramers 
constituted by M and H protein subunits. M and H protein are encoded by the 
LDHA and LDHB genes respectively. M subunits catalyze the pyruvate 
transformation to lactate but the conversion of pyruvate to acetyl-CoA is favored 
in the presence of H subunits when the ability of the enzyme to catalyze the 
reaction is lowered. Each of the LDH isozymes has its unique subunits 
composition which is summarized in the Table 2. LDH5 is the most important 
isozyme for promoting anaerobic glycolysis; increase in its expression has been 
associated with the aggressiveness and metastasis of various cancer types 
(Koukourakis et al., 2005).  










2.1.3 Pyruvate dehydrogenase (PDH) and pyruvate dehydrogenase kinase 
(PDHK) 
Under normoxic condition, pyruvate which is the end product of 
glycolysis is converted into acetyl-CoA via the action of pyruvate dehydrogenase 
complex (PDHc). The acetyl-CoA then combines with oxaloacetate to form 
citrate which starts the tricarboxylic acid (TCA) cycle. PDH complex is composed 
of three enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide acyltransferase 
(E2) and dihydrolipoamide dehydrogenase (E3) (Reed and Hackert, 1990). 
Sequence of reactions catalyzed by the PDH complex is depicted in Fig. 2.1.3.  
 
Fig. 2.1.3 Sequential reactions catalyzed by PDH complex in which pyruvate 
is decarboxylated to form acetyl-CoA.  
 
In view of its central role in linking glycolysis and TCA cycle, PDH is 
tightly regulated by three mechanisms: inhibition by acetyl-CoA and NADH, 
stimulation by reduced energy in the cell and inhibition by regulatory 
phosphorylation of its E1 subunit at Ser232, Ser293 and Ser300 by pyruvate 
dehydrogenase kinase (PDHK) (Holness and Sugden, 2003; Sugden and Holness, 
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2003). There are four known isozymes of PDHK expressed in a tissue-specific 
manner in vertebrates (Roche et al., 2001) , each has a different reactivity towards 
the three phosphorylation sites. Among all, PDHK1 and PDHK3 have been 
reported to be hypoxia-inducible (Denko et al., 2003; Papandreou et al., 2006). 
The inhibition caused by PDHK could be reversed by the two pyruvate 
dehydrogenase phosphatases (PDP1 and PDP2) which dephosphorylate the E1α 
subunit and activate the enzyme. 
2.1.4 Mitochondrial biogenesis 
The elevated protein levels of hypoxia-inducible factor 1 (HIF-1) seen in 
most cancer cells has been shown to inhibit mitochondrial biogenesis (Zhang et 
al., 2007). This provides evidence to Warburg’s theory that aerobic glycolysis 
observed in cancer cells is due to defective mitochondrial respiration. 
Mitochondrial biogenesis is defined as the growth and division of pre-existing 
mitochondria (Ventura-Clapier et al., 2008). It can be affected by environmental 
stimuli and cellular stress such as low temperature, exercise, oxidative stress, 
caloric restriction, cell division, renewal and differentiation. Mitochondrial 
biogenesis involves the variations in number, in size and in mass. During this 
process, majority of mitochondrial proteins comes from the nuclear genome 
whereas the mitochondrial genome encodes only 13 subunits of the electron 
transport chain complexes I, III, IV, V, ribosomal and transfer RNAs. Expressions 
of the various genes are regulated by a network of transcription factors. 
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) is the master regulator of mitochondrial biogenesis (Puigserver et al., 
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1998). PGC-1α does not bind to DNA but it is a transcriptional co-activator that 
interacts and activates various transcription factors, including nuclear respiratory 
factors (NRF-1 and NRF-2). The NRF-1 and NRF-2 in turn promote the 
expression of mitochondrial transcription factor A (mtTFA) which directly drives 






2.2 Results and Discussions 
2.2.1 Higher protein expressions of hypoxia-inducible factor alpha subunits 
(HIF-1alpha and HIF-2alpha) in ccRCC tumor lysate 
Deactivation of VHL gene, the most common mutation in ccRCC leads to 
the stabilization and increase of hypoxia inducible factors (Nyhan et al., 2011). 
Consistent with earlier reports, HIF-1α and HIF-2α were upregulated in 83.3% 
(5/6) and 87.5% (7/8) of ccRCC tumors respectively (Fig. 2.2.1a & 2.2.1b) HIF-
2α expression in sample #6 was excluded as the blot was damaged at that region.  
All the tumor samples that showed an augmentation in HIF-1α expression 
had a corresponding increase in HIF-2α expression suggesting that their protein 
stability are regulated in a similar manner. Indeed, the oxygen-dependent-
degradation domains of the two HIF-α subunits, are highly homologous and thus 
explaining the identical trend between the two (Loboda et al., 2010). Although 
HIF-1α and HIF-2α are structurally similar in their DNA binding and 
dimerization domains, the difference in their transactivation domains imply that 
their effect on the expression of some genes may vary. Results by Hu et al 
indicate that despite of sharing some common targets, HIF-1α but not HIF-2α is 
involved in regulation of transcription of genes encoding enzymes involved in the 
glycolytic pathway (Hu et al., 2003). On the other hand, HIF-2α was suggested as 
a renal cancer oncogene as its overexpression is important for the development of 






Fig. 2.2.1 Western blot analysis of hypoxia-inducible factor alpha subunits, 
(a) HIF1α and (b) HIF2α.  
Lysates prepared from human ccRCC tumor and paired, adjacent normal tissues 
were probed with the respective antibodies. Of note, sample #8 was derived from 
an unclassified renal cell carcinoma and therefore was excluded from percentage 
calculation shown in the results. Intensity of bands was quantified using the 
ImageJ software and expressed as relative to α-tubulin. HIF1α and HIF2α were, 
respectively, higher in 5 out of 6 and 7 out of 8 ccRCC tumor (T) as compared to 
the corresponding normal tissues (N).  No replicate was performed due to the 
limited lysate derived from the tiny piece of human tissue. 
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2.2.2 Increased expression of HIF-regulated glycolytic gene: Hexokinase II 
(HKII) and Lactate dehydrogenase isoenzyme V (LDH5) in ccRCC tumor 
lysate 
Corroborating with the enhanced expression of HIF-1α, protein expression 
of HKII and LDH5 were also upregulated in sample #1, #2, #5, #9 and #10. 
Overall expression of HKII and LDH5 are higher in 88.9% (8/9 in Fig. 2.2.2a) 
and 77.8% (7/9 in Fig. 2.2.2b) of ccRCC tumor lysate as compared to their 
adjacent non-neoplastic tissue.  
Interestingly, HKII and LDH5 expressions also correlated to those of HIF-
2α indicating a possible role of HIF-2α in regulating their transcriptions although 
they were previously demonstrated as unique targets of HIF-1α (Hu et al., 2003). 
In fact, the direct association between LDH5 up-regulation and HIF-1α and HIF-
2α accumulation had been reported (Koukourakis et al., 2005).  
Lactic acid produced by the elevated aerobic glycolysis contributes to the 
acidification of intratumoral environment which facilitates tumor growth and 
invasion (Walenta et al., 1997; Walenta et al., 2000). Unlike cancer cells whose 
proliferation is not affected by low pH, normal cells grow slower (Ceccarini and 
Eagle, 1971). Furthermore, acidosis causes apoptosis (Park et al., 1999), increases 
the degradation of extracellular matrix (Rozhin et al., 1994) and retards the 








Fig. 2.2.2 Western blot analysis of enzymes which are known to be targets of 
HIF1α.  
(a) Hexokinase II (HKII) and (b) lactate dehydrogenase isoenzyme V (LDH5) 
were found to be highly expressed in the ccRCC tumor lysate (T) as compared to 
the patient-matched normal tissue (N). Of note, sample #8 was derived from an 
unclassified renal cell carcinoma and therefore was excluded from percentage 
calculation shown in the results. Intensity of bands was quantified using the 
ImageJ software and expressed as relative to α-tubulin, the loading control. 
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2.2.3 Elevated expression of pyruvate dehydrogenase kinase (PDHK1) and 
reciprocal loss of pyruvate dehydrogenase (PDH) expression and activity in 
ccRCC tumor 
Other than HKII and LDH5, pyruvate dehydrogenase kinase 1 (PDHK1) is 
another downstream target of HIF-1α. It was found to be higher in 66.7% (6/9) in 
ccRCC tumor sample (Fig. 2.2.3a). There was a correlation between the 
expression of HIF-1α and PDHK1 since the latter is a known target of the former 
(Kim et al., 2006; Papandreou et al., 2006). 
PDHK1 phosphorylates and inhibits pyruvate dehydrogenase (PDH) 
activity. Examination on the total and active PDH activity of sample # 9 and #10 
which showed higher PDHK1 expression revealed a complete loss of activity 
measured in mitochondria isolated from the tumor (Fig. 2.2.3b). The experiment 
was not performed on the other samples due to insufficient mitochondrial extract.  
However, the absence of even the total PDH activity in contrast to the 
significant activity observed in normal mitochondria could not be explained by 
the inhibition of PDHK1 since phosphorylation will only attenuate the active 
fraction of the PDH activity. Therefore, the protein expression of PDH E1α was 
studied. There was minimal amount of PDH E1α present in the ccRCC tumor (Fig. 
2.2.3c) which could explain why PDH activity was not detected. Synthesis of 
pyruvate dehydrogenase complex could be compromised due to the low level of 
its inducing metabolite, pyruvate (Dietrich and Henning, 1970). Of note, the PDH 
E1α expression was inversely related to their corresponding PDHK1 counterparts 
(Fig. 2.2.3a).  
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The loss of PDH enzymatic activity in ccRCC tumor deprives the Krebs 
cycle of acetyl-coA and leads to shortage of TCA metabolites and reducing 
equivalents for oxidative phosphorylation. This forces the cancer cells to seek for 












Fig. 2.2.3 Pyruvate dehydrogenase kinase (PDHK) and its relationship with 
pyruvate dehydrogenase complex (PDHc).  
(a) Antibody against PDHK1 was used to detect the protein expression level 
of PDHK1 and it was found to be generally higher in the ccRCC tumor as 
compared to their normal counterparts. 
(b) PDH enzymatic activity The total and active PDH enzyme activities 
were present in the mitochondrial extracts of normal (N) but absent from 
those of the tumor (T).   
(c) Protein expression of PDH complex was probed using an antibody against 
its PDHE1α subunit.   PDH is regulated by phosphorylation of three serine 
residues on the E1α subunit (Dahl et al., 1987; Yeaman et al., 1978). An 
inverse relationship between the protein levels of PDHK1 and PDHE1α 







2.2.4 ccRCC tumor has lower protein expressions of respiratory chain (RC) 
complexes I to V 
Warburg proposed that injury to respiration in cancer cells is responsible 
for their addiction towards aerobic glycolysis; therefore, the components of the 
respiratory chain were examined. All the respiratory chain (RC) complexes I-V 
(corresponding to NADH dehydrogenase, succinate dehydrogenase, ubiquinol 
dehydrogenase, cytochrome c oxidase and ATP synthase) were uniformly down-
regulated in the ccRCC tumor lysates tested (Fig. 2.2.4). A cocktail of five 
antibodies corresponding to the respective subunits of RC complexes was applied 
in this case (as shown in Table 3). All the subunits detected are nuclear-encoded 
except that of MTCO1 of complex IV. Therefore, the general reduction across the 






Function Encoded by 
I NDUFB8 Accessory subunit that 
transfers electrons from 
NADH to the respiratory 
chain. 
Nuclear DNA 
II SDHB Iron-sulfur protein (IP) 
subunit that transfers electrons 
from succinate to ubiquinone 
(coenzyme Q). 
Nuclear DNA 
III UQCRC2 Core protein 2 is required for 
the assembly of the complex. 
Nuclear DNA 
IV MTCO1 CO1 is the catalytic subunit of 
Complex IV. 
Mitochondrial DNA 
V ATP5A Subunits alpha and beta form 
the catalytic core in F1-
ATPase. 
Nuclear DNA 






Fig. 2.2.4 Protein expressions of respiratory complexes I to V. 
The cocktail employed contained antibodies to probe for the following subunits of 
the five respiratory complexes (RC), namely Complex I subunit NDUFB8, 
Complex II subunit 30kDa, Complex III subunit Core 2, Complex IV subunit I 
and ATP synthase subunit α. Expressions of RC I to V were uniformly reduced in 
tumor (T) as compared to corresponding normal (N) lysate. Bands of complex I 
required a longer exposure to be visible. Actin which was meant for loading 














2.2.5 Mitochondrial enzymes activities  
In agreement with the protein expressions, enzymatic activities of RC 
Complex I (NADH dehydrogenase) and Complex V were compromised in the 
ccRCC tumor. There was a 3.3-fold reduction of NADH dehydrogenase activity 
in tumor mitochondria of sample #1 as compared to its normal counterpart (Fig. 
2.2.5a). Sample #9 and #10 displayed a 6.2- and 4.7-fold reduction in the 
Complex V activity measured as the oligomycin-sensitive Fo-ATPase activity (Fig. 
2.2.5b). This finding is supported by earlier reports demonstrating the lower 
protein expressions and activities of respiratory complexes in ccRCC (Meierhofer 
et al., 2004; Simonnet et al., 2002). 
In order to determine if the down-regulated RC activities were due to the 
difference on the content of intact mitochondria, activity of citrate synthase (CS) 
was measured. CS is commonly used as a mitochondrial, quantitative marker 
enzyme (Holloszy et al., 1970; Hood et al., 1989; Williams et al., 1986) because 
its activity in a specific tissue is frequently constant when expressed per mg of 
mitochondrial protein. CS activity was found to be negligibly compromised in 
tumor of sample #9 in contrast to 33% increase in tumor of sample #10 (Fig. 
2.2.5c).  
Apart from citrate synthase, malate dehydrogenase is another enzyme 
involved in the Krebs cycle. It reversibly catalyzes the conversion from malate to 
oxaloacetate at the expense of NAD to form NADH. There was no significant 
difference in malate dehydrogenase (MDH) activity between the normal and 




Fig. 2.2.5 Activities of mitochondrial enzymes. 
(a) NADH dehydrogenase (RCI) activity   Complex I activity was measured 
in freeze-thawed mitochondrial extracts.  There was a significant 
difference in RCI enzymatic activity between the tumor (T) and matched 
normal (N) tissues with ***p<0.005 for n=3. 
(b) FoF1-ATPase enzymatic activity   As represented by its oligomycin 
sensitivity, the FoF1-ATPase activity determined in two freeze-thawed 
mitochondrial extracts was quite compromised in ccRCC tumor (T) as 
compared to matched normal (N) tissues. 
(c) Citrate synthase (CS) activity   CS activity was comparable between the 
tumor (T) and patient-matched (N) mitochondrial extracts. 
(d) Malate dehydrogenase (MDH) activity   There was no significant 
difference in MDH activity between freeze-thawed mitochondrial extracts 






2.2.6 Reduced expression of transcription factors: mtTFA, PGC-1α and 
NRF-1 in mitochondrial biogenesis 
  The overall decreased protein levels of respiratory complexes described 
above suggested a possible global decrease in mitochondrial genesis which led us 
to measure the associated transcription factors: mitochondrial transcription factor 
A (mtTFA), peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) and the nuclear respiratory factor 1 (NRF-1). Our Western blot 
analyses showed lower expressions of mtTFA (Fig. 2.2.6a), and PGC-1α except 
for samples #6, #8 or/and #7 (Fig. 2.2.6b).  In a separate blot of seven sets of 
tissue samples, NRF-1 was also lower in tumor tissues (Fig. 2.2.6c).  Together, a 
deficient mitochondrial biogenesis was implicated.  
  Indeed, compromised mitochondrial biogenesis has been attributed to the 
deficiency of von Hippel-Lindau factor (VHL)  since mitochondrial DNA, 
respiratory chain contents and mtTFA were upregulated when VHL is restored in 
VHL-deficient ccRCC cells (Hervouet et al., 2005). This is substantiated by the 
finding that HIF1α mediates the reduction of mitochondrial mass and oxygen 










Fig. 2.2.6 Protein expression of transcription factors involved in 
mitochondrial biogenesis. 
The three transcription factors are (a) mitochondrial transcription factor A 
(mtTFA), (b) peroxisome proliferator-activated receptor gamma coactivator-1-
alpha (PGC-1alpha) and (c) nuclear respiratory factor (NRF-1). The protein 
expressions of all three were generally down-regulated, suggesting a decrease in 







CHAPTER 3 OXIDATIVE PHOSPHORYLATION (OXPHOS) CAPACITY 
AND ROS PRODUCTION IN CLEAR CELL RENAL CELL 
CARCINOMA (CCRCC) 
3.1 Introduction 
3.1.1 Oxidative phosphorylation in tumor cells 
The phenomenon of increased dependence on glycolysis due to defective 
mitochondrial functions were generally applied to all types of cancer after 
Warburg’s finding with solid and ascites tumor cells was reported in 1956 
(Baggetto, 1992; Pedersen, 1978; Robey et al., 2005; Rossignol et al., 2004; 
Stubbs et al., 2003; Warburg, 1956b). Indeed, all tumors exhibit elevated 
glycolysis and many are characterized by compromised oxidative metabolism 
(Pedersen, 1978) which is associated with lower pyruvate oxidation (Baggetto and 
Lehninger, 1987), truncated TCA cycle (Parlo and Coleman, 1984), change in 
mitochondrial ultrastructure (Hoberman, 1975; Springer, 1980), lower 
mitochondrial content per cell and deficiency in respiratory chain complexes 
(Lichtor and Dohrmann, 1987; Pedersen, 1978), Crabtree effect in which 
oxidative phosphorylation was inhibited by glycolysis (Melo et al., 1998; 
Rodriguez-Enriquez et al., 2001; Sauer, 1977; Sussman et al., 1980), increased of 
ATP synthase inhibitory peptide (Bravo et al., 2004; Solaini and Harris, 2005) or 
increased mtDNA damage by oxidative stress (Carew and Huang, 2002; 
Meierhofer et al., 2006; Penta et al., 2001).  
However, there are contradicting results that challenge the explanations 
mentioned above. In AS30-D hepatoma, citrate flux in Krebs cycle was not 
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truncated and the activities of TCA cycle enzymes were found to be 1-30 times 
higher than that of normal liver mitochondria (Briscoe et al., 1994; Dietzen and 
Davis, 1993). Enzymatic activities of NADH cytochrome c reductase was 
increased by 2 to 5 fold in brain tumors despite the lower expressions of 
respiratory chain components (Lichtor and Dohrmann, 1987; White and Nandi, 
1976). Inhibitory peptide of ATP synthase was shown to affect only the 
hydrolytic reaction when mitochondrial membrane potential (MMP) was low 
(Solaini and Harris, 2005) but not the synthetic reaction which was supported by 
high MMP; therefore, the mitochondrial ATP synthesis should not be decreased 
by the lower level of this protein. Although correlation was observed between 
mutation in mtDNA and ROS production accompanied with lower mitochondrial 
functions in oncocytic thyroid carcinomas (Bonora et al., 2006), human renal 
carcinoma displays low mtDNA mutations which should not be responsible for 
the compromised aerobic energy capacity (Meierhofer et al., 2006) in this tumor. 
In fact, tumor cell lines were shown to have elevated rates of respiration 
(Weinhouse, 1956) in which 85-90% of the respiration rate in AS-30D and HeLa 
were sensitive to the ATP synthase inhibitor, oligomycin indicating their reliance 
on oxidative phosphorylation. The higher activities of mitochondrial malic 
enzyme (Mandella and Sauer, 1975) and phosphate-dependent glutaminase 
(Matsuno and Goto, 1992; Molina et al., 1995) in tumor cells as compared to their 
original tissue counterpart suggest mitochondria in cancer cells are active. 
Furthermore, the supply of mitochondrial ATP required for cell cycle transition 
from resting to active proliferating state in Ehrlich tumor cells (Muller et al., 1986) 
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as well as the oxidation of pyruvate and glutamine in glycolytic gliomas during 
low glucose condition (Griguer et al., 2005) demonstrates the existence of fully 
functional mitochondria in tumors. We have also shown that OXPHOS-competent 
mitochondria are present in ovarian cancer tissues and skin fibroblasts from 
human keloid as shown by studies in our lab (Lim et al., 2011; Vincent et al., 
2008). 
Enhancement of glycolysis accompanied by impaired mitochondria could 
be peculiar to certain cancer types but is definitely not a universal mechanism. 
Thus, the oxidative metabolism of each cancer type has to be assessed before any 
precise conclusion can be drawn. Apart from the heterogeneity of tumors, 
reduction in the protein expression and/or enzymatic activity of a particular 
enzyme might not necessarily be detrimental to the metabolic pathway. Therefore, 
a much appropriate approach is employed here to examine the OXPHOS capacity 
via the measurement of ATP synthesis, oxygen consumption rate and 
mitochondrial membrane potential in intact, isolated mitochondria from ccRCC 




3.1.2 Reactive oxygen species (ROS)  
Mitochondria are the major production site of reactive oxygen species 
(ROS) whereby electrons leak out from the electron transport chain and combine 
with molecular oxygen to form superoxide anion (O2-·), a precursor of most ROS. 
Sites of superoxide formation are depicted in Fig. 3.1.2. The contribution of each 
site to the overall superoxide level is organ specific and also depends on how 
reduced the respiration chain is (Barja, 1999). Higher superoxide production is 
anticipated when the mitochondria are not synthesizing ATP and have a high 
mitochondrial membrane potential due to the sluggish electron transfer. Complex 
I is the primary superoxide generator in the brain under normal conditions (Barja, 
1999; Herrero and Barja, 1998) and it is also responsible for ROS produced in 
pathological conditions such as in Parkinson’s disease (Betarbet et al., 2002; 
Herrero and Barja, 1998; Kushnareva et al., 2002; Trojanowski, 2003). In contrast, 
superoxide produced in heart and lung mitochondria originate from Complex III 
(Turrens and Boveris, 1980; Turrens et al., 1982). Superoxide generated at the 
intermembrane space can be converted to hydrogen peroxide (H2O2) by the action 
of copper zinc superoxide dismutase (CuZnSOD) which is used to reduce 
cytochrome c or be released into the cytoplasm via voltage-dependent anion 
channels (Han et al., 2003).  Superoxide formed in the matrix however is 





Fig. 3.1.2 Sites of superoxide production. Reproduced from Journal of 
Physiology, 552, Turrens JF, Mitochondrial formation of reactive oxygen species, 
page 336, 2003, with permission from John Wiley and Sons (License Number: 
3445700946667). 
The three main mammalian superoxide dismutases are SOD1, SOD2 and 
SOD3. SOD1 and SOD3 contain copper and zinc in their active site and SOD1 is 
found in the intermembrane space and cytosol whereas SOD3 is localized 
extracellularly. SOD2 is the manganese SOD that is exclusively distributed in the 
mitochondria. Hydrogen peroxide produced by dismutation of superoxide is then 
fully reduced to water or partially reduced and gives rise to one of the strongest 
oxidants, hydroxyl radical (·OH). Superoxide can also react with radicals such as 
nitric oxide (NO·) and produce another potent oxidant, peroxynitrite (ONOO-) 
(Beckman and Koppenol, 1996; Radi et al., 2002). Both hydroxyl radical and 
peroxynitrite trigger the deleterious effect on the cells upon reacting with lipids, 
nucleic acids and proteins. 
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3.2 Results and Discussions 
3.2.1 ccRCC tumor mitochondria are capable of synthesizing ATP  
 ATP synthesis by isolated mitochondria when fortified with exogenous 
ADP and respiratory substrates measures the OXPHOS capacity. It involves the 
oxidation of added substrates followed by the transfer of electron from NADH / 
FADH2 to oxygen by a series of complexes which coupled to the phosphorylation 
of ADP to form ATP.  
The rate of ATP biosynthesis from ADP in the presence of 
malate/glutamate (RCI substrates), succinate (RCII substrate) or N,N,N′,N′-
tetramethyl-p-phenylenediamine (TMPD) /ascorbate (artificial RCIV substrates) 
was comparable in two of the three pairs of tumor and normal tissues as shown in 
Fig. 3.2.1a and Fig. 3.2.1b.  However, less ATP was generated from all substrates 
examined for the sample #4T shown in Fig. 3.2.1c which was probably due to the 
extensive areas of hemorrhage and necrosis as revealed by the pathological 
analysis (Table 1).   
 Enzymatic activity of respiratory complex I (NADH dehydrogenase) was 
shown to be lower in the mitochondrial extract of sample #1T; however, ATP 
formation given rise from RCI substrates, malate/glutamate was surprisingly not 







Fig. 3.2.1 Biosynthesis of ATP in intact mitochondria isolated from ccRCC 
tumor and patient-matched normal tissue. 
5mM each malate/glutamate (RCI substrates), 10mM succinate (RCII 
substrate)/5µM rotenone and 1mM TMPD/5mM ascorbate (artificial electron 
donors for RCIV)/2µg/ml antimycin A were used. 125µM ADP was added in all 
conditions containing respiratory substrates. The rate of ATP biosynthesis was 
only compared for sample #1 as shown in Fig. (a) for n=3; *p<0.05. No 




3.2.2 ccRCC tumor mitochondria exhibit comparable oxygen consumption 
rate   
The capacity and function of the intact mitochondria isolated from ccRCC 
tumor tissues and their normal counterparts were also determined using 
polarographic-based measurements of oxygen consumption. The flux control ratio 
which represented the oxygen consumption rate was depicted in Fig. 3.2.2.  
State 4 respiration was achieved by the oxidation of succinate plus 
rotenone without ADP, labeled as S(ROT). In this case, rotenone was added to 
inhibit NADH dehydrogenase and therefore prevent the formation of oxaloacetate 
from malate by the action of malate dehydrogenase that required NAD+ as a 
cofactor. Accumulation of oxaloacetate (which is a potent competitive inhibitor of 
succinate dehydrogenase (Wojtczak et al., 1969) due to its inability to permeate 
the mitochondrial inner membrane will lead to the inhibition of succinate 
dehydrogenase which is unfavorable under this assay setup. On the other hand, 
State 3 respiration was attained with saturated amount of ADP for the estimation 
of coupled OXPHOS capacity.  
A comparable degree of OXPHOS was observed in all three sets of 
samples (Fig. 3.2.2) except for minimal State 4 respiration of succinate which was 





Fig. 3.2.2  Oxygen consumption in intact mitochondria isolated from ccRCC 
tumor and corresponding normal tissue. 
A comparable degree of oxygen flux (rate of oxygen consumption) control ratio 
was evident in both tissues using 10mM succinate as respiratory substrate in the 
presence of 0.5µM rotenone, an inhibitor of NADH dehydrogenase, except for 
tumor sample #4.  OXPHOS which was measured in the presence of 250µM ADP 
was comparable in mitochondria isolated from normal (N) and ccRCC tumor (T) 
tissues.  However, state 4 respiration of succinate plus rotenone appeared 














3.2.3 Mitochondria from ccRCC tumor exhibit higher basal mitochondrial 
membrane potential (MMP) 
The JC-1 fluorescent probe was used as a semi-quantitative method to 
evaluate the capacity of mitochondria to induce membrane potential (MMP) by 
sequential additions of respiratory substrates followed by de-energization with the 
inhibitors. JC-1 is a lipophilic, cationic probe and it is taken up into the 
mitochondria due to the negative transmembrane potential in the matrix. When 
more of the JC-1 green monomers enter the mitochondria due to the polarization 
of mitochondrial membrane, they form aggregates which have a red fluorescence 
causing a shift in the emission wavelength from 535nm to 595nm. This is also 
reflected by the reciprocal change of the green and red fluorescence. ADP was 
initially introduced to the assay system in order to deplete the endogenous 
substrates present in the isolated mitochondria (Chance and Williams, 1955) by 
promoting the coupling between oxidation and phosphorylation.  
Of note, the term “basal MMP” used throughout this thesis corresponds to 
State 2 respiration in which the MMP was measured in the presence of ADP but 
without addition of any respiratory substrates/inhibitors. In contrast, the term 
“inherent or endogenous MMP” is the MMP of mitochondria in the assay buffer 
containing phosphate but without addition of ADP and respiratory 
substrates/inhibitors which corresponds to State 1 respiration. 
Higher basal MMP was detected in mitochondria isolated from ccRCC 
tumor (dotted line) when compared to the matched normal tissue (solid line) as 
shown by steeper gradients marked by asterisks in Fig. 3.2.3b, 3.2.3d and 3.2.3f in 
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the presence of ADP.  The MMP was further increased by substrates of 
respiratory complex I (also known as NADH dehydrogenase), malate and 
glutamate (Mal/Glut) followed by inhibition of NADH dehydrogenase by 
rotenone. The effect of subsequent addition of complex II substrates, succinate 
(Succ) was comparable in the normal samples (Fig. 3.2.3a, 3.2.3c and 3.2.3e but 
variable in the three tumor samples shown in Fig. 3.2.3b, 3.2.3d and 3.2.3f with 
the last showing the least response. The MMP was eventually collapsed by the 
addition of antimycin A (AA), an inhibitor of respiratory complex III. 
Overall, intact mitochondria isolated from ccRCC tumor tissues are able to 
carry out the essential mitochondrial activities involved in OXPHOS. 
Energization of MMP by respiratory substrates indicates the intactness and 
functionality of the mitochondria isolated from ccRCC. The observations of ATP 
biosynthesis and increase in the oxygen flux in response to ADP demonstrate the 
coupling of oxidation of succinate to phosphorylation of ADP. However, it must 
be iterated that exogenous ADP and respiratory substrates were added in all the 
measurements of OXPHOS; thus the results represent the potential of the isolated 
mitochondria to perform OXPHOS when substrates are available. On a side note, 
the aberrant ATP biosynthesis, oxygen flux and MMP were noted with succinate 
in the tumor sample #4 which could be due to the presence of extensive necrosis 








Fig. 3.2.3 Mitochondrial membrane potential in intact mitochondria isolated 
from ccRCC tumor and corresponding normal tissue. 
The basal MMP, evident in the presence of 125µM ADP but before the addition of 
mal/glut was higher in mitochondria isolated from ccRCC tumor tissues as shown 
by the asterisks in Fig. (b), (d) and (f) as compared to the matched adjacent 
normal tissues in Fig. (a), (c) and (e).  X- and y- axes represent, respectively, the 
intensity of fluorescence and time (min).  Solid lines denote the red fluorescence 
of the JC-1 aggregates and dotted lines the green fluorescence of the monomers; 
these two measurements showed a reciprocal relationship.  The MMP was 
induced by addition of 5mM each malate and glutamate (Mal/Glut) which was 
inhibited by 5µM rotenone (ROT) followed by re-energization by 10mM 
succinate (Succ) with subsequent inhibition with 4µg/ml antimycin A (AA, an 




3.2.4 ccRCC tumor mitochondria produced higher reactive oxygen species 
(ROS)  
The high basal MMP observed in the ccRCC tumor creates resistance for 
the electrons to be passed down the electron transport chain. This could lead to 
higher formation of superoxide. Measurement of ROS produced by normal and 
ccRCC tumor mitochondria were performed using the oxidative stress sensitive 
probe, 2′,7′-dichlorofluorescin diacetate (DCFDA) which detects a range of 
radicals including peroxynitrite (ONOO-), hydrogen peroxide (H2O2) in 
combination with cellular peroxidases and hydroxyl radical (·OH) (Myhre et al., 
2003). Result in Fig. 3.2.4 showed that under basal condition (in phosphate 
buffered saline), tumor mitochondria of sample #6 and #9 produced higher level 






Fig. 3.2.4 ROS production in intact mitochondria isolated from ccRCC 
tumor and patient-matched normal tissues.  
ROS production was examined by using the fluorescence probe, 2′, 7′-
dichlorofluorescin diacetate (DCFDA) which could be oxidized by various ROS 
including peroxynitrite (ONOO-), hydrogen peroxide (H2O2) in combination with 
cellular peroxidases and hydroxyl radical (·OH). ccRCC tumor mitochondria 
generated higher level of ROS in the phosphate-buffered saline (PBS) and it is 




3.2.5 The higher ROS generated by ccRCC tumor mitochondria is supported 
by oxygen radicals other than hydrogen peroxide 
To further dissect if the higher ROS production was also reflected in 
hydrogen peroxide production, H2O2 released by the mitochondria was captured 
using the Amplex red™ reagent. Surprisingly, rate of H2O2 generation was 
significantly lower in ccRCC tumor mitochondria of sample #9 and that was also 
true in sample #8 which was an unclassified renal cell carcinoma (Fig. 3.2.5). 
Therefore, the higher ROS production in ccRCC tumor mitochondria was unlikely 
to be contributed by hydrogen peroxide.  
 
Fig. 3.2.5 Hydrogen peroxide released by intact mitochondria isolated from 
ccRCC tumor and patient-matched normal tissues.  
Amplex ® red reagent in combination of peroxide was employed to specifically 
detect the release of hydrogen peroxide from mitochondria. Lower level of 
hydrogen peroxide production was detected in the ccRCC tumor mitochondria, 
sample #9. The unclassified renal cell carcinoma, sample #8 showed the same 






3.2.6 Protein expression of MnSOD is higher in ccRCC tumor lysate 
In order to find out why the production of hydrogen peroxide is lower in 
ccRCC tumor mitochondria, the protein expression of MnSOD which is found 
specifically in the mitochondria was examined. 77.8% of ccRCC tumor showed 
higher MnSOD expression (Fig. 3.2.6). In spite of its higher protein expression, 
formation of hydrogen peroxide was lower in the tumor mitochondria of #6 and 
#9 (Fig. 3.2.5).  
However, overexpression of MnSOD does not guarantee the higher 
production of hydrogen peroxide. The rates of superoxide production and H2O2 
removal determine if additional hydrogen peroxide will be detected in a MnSOD 
overexpression system, in this case the ccRCC tumor mitochondria. SODs are 
present far in excess than it substrate (superoxide) and thus SODs are more than 
sufficient to convert the superoxide into hydrogen peroxide provided that 
superoxide production is not limited. Therefore, it is the generation of superoxide 
but not the expression level of MnSOD that controls the H2O2 production. The 
low H2O2 levels could also be contributed by its rapid scavenging by catalase (one 
of the fastest enzyme), glutathione peroxidases and peroxidredoxins.  
Alternatively, H2O2 can be converted to superoxide and then peroxynitrite 
in a reverse reaction of MnSOD when nitric oxide is available (MacMillan-Crow 
and Crow, 2011) which were depicted in Fig. 3.2.6. In this case, the 





Fig. 3.2.6a The forward and reverse reactions of MnSOD. Superoxide 
produced in the reverse reaction reacts with nitric oxide and give rise to 
peroxynitrite, leading to MnSOD inactivation. 
 
 This provides the explanation for the higher DCF fluorescence but low 
H2O2 formation despite the upregulated MnSOD expression in ccRCC tumor 
mitochondria. Further investigations involving determination of superoxide and 
nitric oxide as well as enzymatic activities of catalase, glutathione peroxidases 
and peroxidredoxins would be useful to provide insights into the mechanism 
responsible for the high MnSOD expression but low H2O2 production observed in 






Fig. 3.2.6b Western blot analysis of MnSOD in lysate of ccRCC tumor and 
adjacent normal tissue.  
MnSOD is synthesized as a precursor protein in the cytosol and translocated into 
the mitochondria driven by the mitochondrial targeting sequence. Higher 
expression level of MnSOD was found in the ccRCC tumor as compared to their 









CHAPTER 4 THE HIGHER BASAL MMP IN MITOCHONDRIA 
ISOLATED FROM CLEAR CELL RENAL CELL CARCINOMA (CCRCC)  
4.1 Introduction 
4.1.1 Mitochondrial membrane potential 
Whilst electrons are passed down the series of respiratory complexes at 
the electron transport chain, protons are pumped from mitochondrial matrix to the 
intermembrane space causing the accumulation of H+ in that region. This creates a 
proton gradient across the inner mitochondrial membrane (IMM) leading to the 
establishment of the mitochondrial membrane potential (∆Ψm, an electrical 
gradient) and mitochondrial pH gradient (∆pHm, an H+ chemical gradient) (Boyer 
et al., 1977; Mitchell, 1966; Murphy and Brand, 1987). The former is manifested 
by the positively charged proton and the latter is due to the acidity caused by 
protons.  
The energy stored in the electrochemical gradient (∆p) is used to drive the 
ATP synthesis at ATP synthase (Complex V) in which protons flow back to the 
matrix against its gradient since the IMM is impermeable to proton.  ∆Ψm is 
highly negative with a typical value range from 150-180mV and ∆pHm of 0.5 to 1 
unit giving rise to 30-60mV; therefore, ∆p which is a sum of both ranges from 
180-220mV. The ratio of contribution by both components on the proton gradient 
varies from cell line to cell line with unknown reason (Tzagoloff, 1982). 
The proton gradient regulates the transport of ions and metabolites 
(LaNoue and Schoolwerth, 1979), the translocation of precursor enzymes (Chen 
and Douglas, 1987; Horwich et al., 1987; Schleyer et al., 1982; Verner and Schatz, 
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1987), the synthesis of mitochondrial protein (Abou-Khalil et al., 1986; 
Rabinovitz et al., 1977) and apoptosis (Ly et al., 2003). The mitochondrial 
membrane potential was also reported to be associated with cell growth. Higher 
MMP was observed in cells in exponential growth phase than those in stationary 
phase (Benel et al., 1986; Bertoncello et al., 1985; Darzynkiewicz et al., 1981; 
Doolittle et al., 1987; Mulder and Visser, 1987). Cell differentiation increases or 
decreases the MMP depending on the energy expenditure in the differentiated 
cells (Collins and Foster, 1983; James and Bohman, 1981; Summerhayes et al., 
1982). The proton potential is also required for cell motility since cells along the 
edges of a healing wound exhibited higher MMP (Johnson et al., 1981) which was 
restored to resting level after the wound was covered up. 
Higher MMP in cancer cells was previously reported in a study comparing 
normal epithelial cells and cancer cells derived from tumors of various tissues 
(Lampidis et al., 1983; Summerhayes et al., 1982; Wiseman et al., 1985). There is 
at least 60mV difference in MMP between the normal epithelial cells and 
carcinoma cells (Modica-Napolitano and Aprille, 1987) but the mechanism 




4.1.2 Uncoupling proteins (UCPs) 
Uncoupling proteins (UCPs) are proton transporters that reside in the inner 
mitochondrial membrane. UCP was first used to describe UCP1 which is uniquely 
found in the mitochondria of brown adipocytes. Activation of UCP1 by free fatty 
acid uncouples the ATP production from the mitochondrial respiration and 
dissipates the energy of proton gradient as heat.  
UCP2 and UCP3 are two homologues of UCP1 that share ~56% of their 
amino acid sequence. UCP2 is ubiquitously expressed whereas UCP3 is mainly 
detected in skeletal muscle. The involvement of UCP2 and UCP3 in regulating 
the proton electrochemical gradient is suggested in yeast (Fleury et al., 1997; 
Gimeno et al., 1997; Hinz et al., 1999a; Hinz et al., 1999b; Zhang et al., 1999) and 
mammalian cells (Fink et al., 2002; Hong et al., 2001). However, controversial 
studies show UCP2 and UCP3 do not mimic the role of UCP1 in uncoupling and 
thermogenesis (Golozoubova et al., 2001; Stuart et al., 2001). Besides regulating 
the free radical levels in cells, UCP2 and UCP3 have been suggested to be 
involved in insulin secretion (Hong et al., 2001) and fatty acid metabolism 
(MacLellan et al., 2005) respectively.  
By uncoupling the oxidative phosphorylation (OXPHOS), UCPs collapse 
the mitochondrial membrane potential since protons are shuttled across the IMM 
freely; therefore, it is pertinent to examine the relationship between UCPs and 




In addition to uncoupling proteins, respiratory substrates which feed 
electrons to the respiratory chain are important for the establishment and 
maintaining of MMP.   
Owing to the glucose addiction and diversion of pyruvate-derived carbon to 
lactate production especially during the loss of PDH activity mediated by HIF1α, 
cancer cells seek alternative carbon source to generate building blocks for their 
active proliferation. Glutamine (Gln) which is the most abundant amino acid 
present in the plasma and most tissues (Van Slyke et al., 1973) is the ideal 
candidate to fuel the rapidly dividing cells via the mitochondrial pathway of 
glutaminolysis.  
First of all, glutamine has to be transported from the extracellular 
compartment into the mitochondria in order for glutaminolysis to occur (McGivan 
and Bungard, 2007). In fact, glutamine transporters have been identified on the 
inner mitochondrial membrane (Mates et al., 2009).  
During glutaminolysis, glutamine (Gln) is deaminated to form glutamate 
(Glut) and ammonia via the action of glutaminase. This is followed by the 
deamination of glutamate to produce α-ketoglutarate (α-KG) which is a TCA 
cycle intermediate.  By replenishing the Krebs cycle, glutamine enables the 
production of pyruvate and NADPH by the action of malic enzyme. Pyruvate is 
then converted into acetyl-CoA (if the functional pyruvate dehydrogenase is 
present) which forms citrate in combination with oxaloacetate that produced from 
glutamine-derived α-ketoglutarate. NADPH regeneration leads to the reduction of 
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glutathione for ROS scavenging (Medina, 2001; Tong et al., 2009). However, in 
cases like ccRCC, citrate is probably generated from glutamine-derived α-
ketoglutarate via the reverse TCA cycle due to the diminution of PDH expression 
and activity.  
 
Fig. 4.1.3 Anaplerosis of TCA cycle via glutaminolysis. Reproduced from 
Nature Reviews Molecular Cell Biology, 13, Wellen KE and Thompson CB, A 
two-way street: reciprocal regulation of metabolism and signaling, page 271, 2012, 
with permission from Nature Publishing Group (License Number: 
3445710152912).  
Glutaminase exists as two isozymes, kidney-type and liver-type. They are 
different on the requirement for phosphate, Km for glutamine and pH optima 
(Horowitz et al., 1968; Katunuma et al., 1967; Katunuma et al., 1973). Liver-type 
glutaminase requires low phosphate but high glutamine for its activity (Km=28 to 
42mM) as compared to the kidney-type which demonstrated a Km of 22mM and 
2.2mM for phosphate and glutamine respectively (Horowitz et al., 1968; Huang 
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and Knox, 1976; Katunuma et al., 1967; Pinkus and Windmueller, 1977). 
Glutaminase activity found in extracts of cells and tissues are generally the 
phosphate-dependent, kidney type isozyme (Katunuma and Okada, 1963). 
Tumors of kidney (Katunuma et al., 1972), mammary gland and fetal liver (Knox, 
1976) exhibit higher phosphate-activated glutaminase activity. The correlation 
between glutaminase activity and the degree of malignancy and growth rates was 
observed in the Morris hepatomas (Knox et al., 1969; Knox et al., 1967; Linder-
Horowitz et al., 1969). The role of glutamine in supporting the anaplerosis of 
TCA cycle of tumor cells was also revealed by using 13C NMR spectroscopy 








4.2 Results and Discussions 
4.2.1 The role of uncoupling proteins (UCPs) 
4.2.1.1 The protein expressions of UCPs in tissue lysate of ccRCC tumor and 
the corresponding patient-matched normal 
 UCP1 is normally expressed in the brown adipocytes; therefore, it is not 
surprising to detect negligible UCP1 expression in the normal, human kidney 
tissue lysate. However, higher protein expression was observed in the tumor of 
sample #2, #5, #6 and #7 as compared to their adjacent normal tissue (Fig. 
4.2.1.1a). UCP2 was completely absent in all the ccRCC tumor except sample #7 
(Fig. 4.2.1.1b) and it was accompanied by a reciprocal increase in the protein 
expression of UCP3L (Fig. 4.2.1.1c). UCP3 mRNA exists as two transcripts, 
UCP3L and UCP3S which were generated from a single gene through alternative 
splicing. UCP3S which lacks the last 37 amino acids that represent the region for 
fatty acid and guanine nucleotide regulation (Miroux et al., 1993) is believed to 
have no uncoupling activity (Millet et al., 1998). Although the inverse 
relationship between the UCP2 and UCP3L is interesting, it is not covered here.  
In this thesis, focus has been placed on UCP2 which is normally found to 
be upregulated in cancers such as hepatocarcinoma (Carretero et al., 1998), 
cholangiocarcinoma and oxyphilic thyroid tumor (Baffy, 2010), colon cancer 
(Horimoto et al., 2004; Kuai et al., 2010) and almost all human cancers examined 
(Ayyasamy et al., 2011).  Our finding on the loss of UCP2 indicated its 
uniqueness to ccRCC and it could contribute to the higher mitochondrial 
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membrane potential observed in the ccRCC tumor. The role of UCP2 in 













Fig. 4.2.1.1 Protein expressions of uncoupling proteins (UCPs) in lysate of 
ccRCC tumor and adjacent normal tissue.  
Tissue lysates prepared from ccRCC tumors and their corresponding normal 
counterparts were probed for uncoupling proteins. Intensity of bands was 
quantified using the ImageJ software and expressed as relative to α-tubulin.  
(a) UCP1   Negligible UCP1 expression was seen in the normal kidney tissue 
and it was seen to be upregulated in tumor of sample #2, #5 and #7.  
(b) UCP2   UCP2 was near to absent in the ccRCC tumors. 
(c) UCP3   Two bands were detected for the UCP3 due to the presence of two 
spliced variants, UCP3L and UCP3S. UCP3S lacks the sequence which is 
critical for uncoupling activity and therefore is not discussed here. UCP3L 




4.2.1.2 Effect of genipin, a UCP2 inhibitor on MMP of mitochondria isolated 
from normal tissue 
Genipin, an extract from Gardenia jasminoides is a highly specific 
inhibitor of UCP2 (Mailloux et al., 2010). It has been demonstrated to decrease 
the proton leak mediated by UCP2 in brain tissue, pancreatic β-cells and kidney 
mitochondria (Parton et al., 2007; Zhang et al., 2006). Therefore, the effect of 
genipin on the energization of mitochondrial membrane potential was examined 
in normal, intact mitochondria of sample #10 since there was negligible level of 
UCP2 present in this ccRCC tumor. In Fig. 4.2.1.2, 50µM genipin (represented as 
dotted line) or 0.1% DMSO (vehicle control in solid line) was added before ADP, 
followed by the addition of respiratory substrates and inhibitors. No difference 
was seen between the MMP of control and genipin-treated mitochondria 
suggesting UCP2 might not be involved in MMP regulation. However, only one 












Fig. 4.2.1.2 Effect of genipin, a UCP2 inhibitor on the MMP of normal, intact 
mitochondria isolated from sample #10. 
50µM genipin or DMSO (vehicle control) was added to the assay cuvette in the 
beginning of the run followed by JC-1 dye, 125µM ADP and mitochondria. The 
MMP was then induced by addition of 5mM each mal/glut which was inhibited by 
5µM rotenone (ROT) followed by re-energization by 10mM succinate (Succ) with 
subsequent inhibition with 4µg/ml antimycin A (AA, an inhibitor of respiratory 
complex III) which finally collapsed the MMP. Only the traces of the red 
aggregates were presented and the solid line denotes the control and dotted line 
for genipin-treated. No effect was seen on the MMP since the two traces showed 

















4.2.1.3 Effect of genipin, a UCP2 inhibitor on MMP of 786-O cells 
786-O is a kidney cell line derived from primary clear cell 
adenocarcinoma and the use of this cell line is to mimic the condition of ccRCC 
tumor. UCP2 protein is present in the 786-O cells as shown by the western blot 
analysis using the whole cell lysate (Fig. 4.2.1.3a). Genipin inhibits UCP2 and 
resulted in increase of MMP by 41% when 786-O cells were treated with 200µM 
genipin for 3h. No effect was seen with 50µM genipin (Fig. 4.2.1.3b). 
With reference to this, higher concentrations of genipin might be required 
to show an effect in mitochondria isolated from tissue (Fig. 4.2.1.2). Alternatively, 
the discrepancy between the effect of genipin in isolated mitochondria of normal 
tissue and 786-O cells could be due to the lack of activator in the former. It is 
reported that UCP2 and UCP3 require the presence of activators such as 
superoxide (Brand et al., 2004; Talbot et al., 2003) and reactive alkenals (Echtay 
et al., 2003) in order for it to transport protons and UCP3 knockout exerted no 
effect on the basal proton conductance of isolated mouse mitochondria (Cadenas 
et al., 2002). Mitochondria isolated from patient-matched normal tissue 
apparently have low levels of these activators. Moreover, genipin failed to inhibit 
the exchange of C4 metabolites with radiolabelled phosphate by UCP2 (Vozza et 







Fig. 4.2.1.3 UCP2 regulates MMP in 786-O cells. 
(a) Western blot analysis of UCP2 protein expression of 786-O cell lysate, 
n=3. 
(b) 786-O cells were treated with genipin for 3h in culture medium and the 
mitochondrial membrane potential (MMP) was measured by TMRM 
fluorescence using flow cytometer. The MMP was increased when cells 
are treated with 200µM genipin but no effect was seen with 50µM genipin 
















4.2.1.4 UCP2 overexpression decreases MMP of 786-O cells 
UCP2 was overexpressed in the 786-O cells following 24h transfection 
with Myc-DDK-tagged human UCP2 plasmid (pCMV-UCP2) (Fig. 4.2.1.4a). Our 
recent preliminary study showed that UCP2 overexpression led to the reduction of 
MMP (Fig. 4.2.1.4b). However, statistical significance was not tested as only 
duplicates were performed. Effort to reproduce the results with more replicates to 
achieve statistical significance is now undergoing. Together with higher MMP 
induced by genipin (an inhibitor of UCP2), our results suggested that UCP2 is a 




Fig. 4.2.1.4 Overexpression of UCP2 decreased MMP of 786-O cells. 
(a). Western blot analysis showed the overexpression of UCP2 at protein level in 
the 786-O cell lysate following 24h transfection using empty vector (labeled as 
Control) or pCMV-UCP2 vector (C-terminal Myc-DDK-tagged, labeled as 
UCP2). α-tubulin served as loading control. 
(b). Mitochondrial membrane potential (MMP) of UCP2-overexpressed and 
control cells (transfected with empty vector) was measured by TMRM 






4.2.2 The role of ADP and glutamine-derived respiratory substrates in 
supporting basal MMP in ccRCC tumor mitochondria 
4.2.2.1 ADP  
Higher basal MMP in the presence of ADP was repeatedly seen in the 
tumor mitochondria (Fig. 3.2.3). In order to find out if the MMP is inherently 
higher in the tumor mitochondria or it is due to the effect of fortified ADP, normal 
and tumor mitochondria were added into cuvette containing only the assay buffer 
and JC-1 probes. Only the traces of the JC-1 red aggregates were shown here, 
with solid and dotted lines representing the MMP of normal and tumor 
mitochondria respectively.  
The inherent MMP appeared to be higher in the tumor mitochondria as compared 
to the normal even when ADP was not added in the beginning of the run (Fig. 
4.2.2.1a and 4.2.2.1b). In fact, there was no evidence of MMP in mitochondria 
isolated from two different normal samples. However, the high MMP in tumor 
mitochondria was not sustainable and showing a decrease 2-5min later. The 
declining MMP was stopped by introducing exogenous ADP suggesting the role 
of ADP in maintaining the inherent basal MMP in tumor mitochondria. The 
addition of ADP would normally decrease the MMP since it promotes the return 
of proton into the matrix via the Fo portion of ATP synthase. However, we 
hypothesized that ADP would have inhibited the UCP3 which is upregulated in 
ccRCC tumor as shown in Fig. 4.2.2.1 based on the findings of Echtay et al. 





Fig. 4.2.2.1 Endogenous MMP in mitochondria isolated from ccRCC tissues. 
Endogenous MMP in the absence of added ADP and respiratory substrate.   
Mitochondria isolated from ccRCC tumor sample (a). #16 and (b). #18 (dotted 
line) but not from patient-matched normal tissues (solid line) exhibited an MMP 
without the addition of ADP and respiratory substrate.  Only the intensity of the 
red fluorescence of the J-aggregates is shown. This endogenous MMP was 















4.2.2.2 Complex I-dependent substrate 
If ADP is present to promote the coupling of OXPHOS, there must be 
some endogenous respiratory substrates that provide the reducing equivalents for 
the oxidation to occur. Lower energization with succinate was detected in tumor 
mitochondria suggesting succinate dehydrogenase activity was compromised in 
two of three samples (Fig. 3.2.2d & 3.2.2f). Therefore, the higher basal MMP in 
tumor could probably be contributed by complex I- instead of complex II-
dependent substrates. This was supported by the observation when rotenone, a 
complex I inhibitor collapsed the basal MMP in tumor mitochondria. It was noted 
that the vehicle control containing 0.5% ethanol also slightly reduced the MMP 
(Fig. 4.2.2.2). 
 
Fig. 4.2.2.2 Inhibition of basal MMP in mitochondria isolated from ccRCC 
tumor. 
5µM rotenone, an inhibitor of respiratory complex I, effectively inhibited the 
basal MMP.  Part of the inhibition was due to ethanol which was used to dissolve 





 4.2.2.3 Energization of MMP in mitochondria isolated from ccRCC tumor 
tissues by glutamine and its derived respiratory substrates 
 The inhibition of rotenone shown in Fig. 4.2.2.2 inferred that complex I-
dependent substrates are involved in supporting the basal MMP of tumor 
mitochondria. However, PDH activity has been shown to be negligible/absent in 
the tumor mitochondria (Fig. 2.2.3b); thus substrates derived from the TCA cycle 
would therefore be minimal. The alternative carbon source that fuels the Krebs 
cycle comes from glutaminolysis. Therefore, the ability of mitochondria isolated 
from ccRCC tumor in utilizing glutamine and its derived, complex I-dependent 
respiratory substrates, namely the glutamine, glutamate, α-ketoglutarate and 
isocitrate was examined. 
 Fig. 4.2.2.3 showed the traces of the red fluorescence of the JC-1 
aggregates, illustrating the induction of MMP by (a) glutamine, (b) glutamate, (c) 
α-KG and (d) isocitrate in sample #15, #16 and #18.  Glutamine was included as it 
is known that glutaminase activity is high in renal cells (Curthoys and Watford, 
1995). All these substrates were effective in eliciting the MMP in mitochondria 
isolated from both normal and ccRCC tumor tissues.  Of note, the higher basal 
MMP in tumor mitochondria prior to the addition of each of these four respiratory 








Fig. 4.2.2.3 Mitochondrial membrane potential (MMP) from glutamine and 
its derived respiratory substrates. 
(a). Glutamine (Gln), (b). glutamate (Glut), (c). α-ketoglutarate (α-KG) and (d). 
isocitrate (Iso) were able to energize mitochondria to produce an increased MMP. 
In some case, rotenone (ROT), succinate (SUCC) and/or antimycin A (AA) were 
also introduced. The intensity of the red fluorescence of the J-aggregates is shown 
with solid lines for the normal tissues and dotted lines for tumor tissues. In all 
traces, the MMP prior to the addition of the respiratory substrate was always 
higher in mitochondria isolated from ccRCC (indicated by asterisks) which was 
also shown previously in Fig. 3.2.2.3. Left and right panels (numbered as 1 & 2) 
are traces obtained from isolated mitochondria from different tissue samples 







4.2.2.4 ccRCC tumor mitochondria are able to utilize glutamine and its derived 
respiratory substrates for ATP biosynthesis 
In addition to measurement of MMP, ATP biosynthesis derived from 
glutamine, glutamate, α-KG and isocitrate was also investigated. The rate of ATP 
biosynthesis from ADP only, glutamate, α-KG and isocitrate was higher in 
ccRCC tumor compared to patient matched normal tissues (Fig. 4.2.2.4). The 
significantly higher rate of ATP synthesis with only ADP in tumor mitochondria 
suggesting either a higher level of endogenous respiratory substrate or higher 
activity of mitochondrial kinases e.g. adenylate kinase (AK) or creatinine kinase 
(CK) (Noma et al., 2001; Payne and Strauss, 1994) which converts ATP and AMP 
to ADP, vice versa. These kinases were however not measured in our study. 
In contrast, tumor has a lower rate of ATP production from glutamine but 
achieving 79% of that in normal. As compared to mitochondria isolated from 
normal tissue, the loss of ability to generate more ATP from glutamine than other 
glutamine-derived substrates in the tumor mitochondria suggested a lower 
mitochondrial uptake of glutamine or compromised glutamine conversion to 
glutamate. However, both have been suggested to be upregulated in cancers 
(Fuchs and Bode, 2005; Hensley et al., 2013; Wise et al., 2008). It is noteworthy 
that the result was obtained with only one sample and this experiment need to be 
repeated in future samples. 
Interestingly, 2mM glutamine produced a higher rate of ATP biosynthesis 
compared to 5mM glutamate, 2.5mM α-KG or 5mM isocitrate in normal 
mitochondria.  This could be due to the more rapid entry of glutamine through the 
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kidney mitochondrial membrane as compared to glutamate which penetrates very 
slowly (Kovacevic et al., 1970).  
 
 
Fig. 4.2.2.4 ATP synthesis from glutamine and its derived respiratory substrates. 
The rate of ATP biosynthesis from the oxidation of glutamate, α-ketoglutarate and 
isocitrate (but not of glutamine) in the presence of 125µM ADP was higher in 
mitochondria isolated from ccRCC tumor when compared to the normal tissues 
(*p<0.05, **p<0.01, ***p<0.005 with n=3).  It was noted that ATP produced from 
2mM glutamine was significantly more than that produced by 5mM glutamate, 








4.2.2.5 Glutaminolysis in ccRCC tumor  
 Role of glutaminolysis as the alternate energy source in ccRCC tumor was 
further examined by measuring the protein expression of kidney-type (K-type) 
mitochondrial glutaminase (KGA/GLS1). KGA is a phosphate-activated 
amidohydrolase that catalyzes the hydrolysis of glutamine to glutamate and 
ammonia. Of the ten samples analyzed, 4 showed higher expression levels of 
KGA in tumor than their corresponding normal counterparts whereas 6 had 
comparable levels of expression (Fig. 4.2.2.5a). Result on glutaminase enzymatic 
activity in the mitochondrial extracts of sample #9, #15 and #16 however was 
variable (Fig. 4.2.2.5b). The higher levels of KGA protein expressions in tumor of 
sample #9 did not translate into higher glutaminase enzymatic activity. 
 It would be interesting to examine the glutaminolysis flux in the ccRCC 











Fig. 4.2.2.5 Protein expression and enzymatic activity of the glutaminase. 
(a) The protein expression of human kidney-type glutaminase (KGA) was 
higher in 4/10 and comparable in 5/10 of ccRCC samples as compared to 
the corresponding patient-matched normal tissue samples.  α-Tubulin was 
the loading control. 
(b) Determination of glutaminase activity in the mitochondrial extracts of 
sample #9, #15 and #16 showed varying results (***p<0.005 with n=3). 














CHAPTER 5 LIMITATIONS, CONCLUSIONS AND FUTURE 
DIRECTIONS  
5.1 Limitations of this study 
The main limitation of our study is the small quantity of mitochondria that 
could be isolated from limited freshly resected human specimen, causing the lack 
of replicates in many sets of data and resulting in semi-quantitative analysis. 
Enzymatic activities such as NADH, Fo-ATPase, CS and MDH were measured in 
freeze-thawed mitochondrial extracts obtained from remaining intact 
mitochondrial preparations.  Understandably, these extracts were limited due to 
the reasons above, which explained the lack of replicates in the data assays as 
shown in Fig 2.2.5. 
During the course of the study, new ideas were generated based on the 
data accrued. It seemed therefore more meaningful to perform different sets of 
other experiments to test our hypotheses rather than to repeat those carried out 
previously. This explained why all the protocols were not used on all tissue 
samples.  Besides, when similar sets of data were obtained from two or three 
tissue samples, it appeared not prudent to continue to measure these same 
parameters. Therefore, only certain samples were used instead of the whole panel, 
consisting of 18 samples. Furthermore, three out of the 18 samples were not 
classified as clear cell renal cell carcinoma in which the pathologists’ reports of 
tissues were only completed after the experiments on freshly isolated, intact 
mitochondria had been performed on the day of surgery.  
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No experimental replicates were performed for Western blot analysis of 
tumor lysate as it was intended as an overview of their protein levels between 
patient-matched paired samples and also due to the scarcity of lysate available for 
screening of multiple proteins. The JC-1 assay employed provides only semi-
quantitative analysis of MMP which suffices to complement the other two 
OXPHOS parameters measured. 
5.2 Conclusions 
The enhanced aerobic glycolysis in cancer cells was proposed to be an 
outcome of impaired respiration by Otto Warburg. This study confirmed the 
glycolytic phenotype in ccRCC as shown by the increased protein expression of 
HIF1α and HIF2α as well as their downstream targets, namely HKII, LDH5 and 
PDHK1. In addition, the reduced expression and activity of mitochondrial 
respiratory complexes resulted from an attenuation of mitochondrial biogenesis 
suggested a deficit of OXPHOS in ccRCC as stipulated in Warburg effect.  
Enzyme activity of PDH, a crucial enzyme that links glycolysis and 
OXPHOS was found to be lost in the ccRCC tumors examined. There is evidence 
of inhibition of PDHc activity brought upon by the phosphorylation of PDHK1. 
However, reports on the status of PDH expression in human cancer tissue has not 
been reported, not to mention the measurement of its enzymatic activity which 
requires the isolation of mitochondria from the human specimen. Most studies on 
cancer cell bioenergetics depend on the use of immortalized cell lines which are 
fortified with excessive nutrients during their culture under atmospheric level of 
oxygen. However, these culture conditions do not reflect the tumor 
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microenvironment with limited oxygen and nutrients. Human cancer tissue is 
therefore a better alternative in accessing the in vivo condition.    
Our measurement of OXPHOS capacity with three different parameters in the 
isolated, intact mitochondria unveils their respiratory competency in ccRCC 
tumors when exogenous substrates are provided.  Our finding of a higher basal 
MMP of mitochondria isolated from ccRCC tumor concurs with hyperpolarized 
mitochondria reported in human cell lines, A549, M059K and MCF-7 (Bonnet, 
2007, 11, 37-51). The regulation of MMP by UCP2 and glutamine-derived 
substrates provide plausible mechanisms underpinning the higher MMP in ccRCC 
tumor mitochondria. Furthermore, the inherent MMP in mitochondria isolated 
from ccRCC tumor tissue which is absent in the normal mitochondria supports the 
use of lipophilic, cationic drugs that selectively accumulate within the cancer 
mitochondria due to the negative charge in the matrix. In addition, the loss of 
UCP2 expression and the reciprocal increase in UCP3 make them potential 
prognostic markers for ccRCC.  
Overall, we propose the metabolic switch of ccRCC from glucose-derived to 
glutamine-derived carbon source due to the deficiency of PDH leads to the higher 
MMP in tumor through the loss of UCP2 and anaplerosis of TCA cycle.  
5.3 Future directions 
This study provided evidence for the presence of respiratory competent 
mitochondria in the ccRCC tumor which coincides with our earlier finding using 
mitochondria isolated from ovarian and peritoneal tumor (Lim et al., 2011). It 
would be interesting to find out if other types of cancers also harbor the functional 
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mitochondria. Mitochondria isolated from ccRCC tumor exhibited higher ROS 
production but the type of ROS was not conclusively evaluated. Although we 
found that hydrogen peroxide was not responsible for the elevated ROS, assays 
determining the level of superoxide and other ROS should be carried out in future. 
With the crucial role of mitochondria play in energy metabolism, apoptosis and 
ROS production, understanding the mitochondrial functions in tumor warrants 
cancer therapy with greater efficiency.     
 UCP2 protein was found to be lost in the ccRCC tumor; however, how and 
at which level (transcriptional or translational) it is regulated was not studied. It 
would be worthwhile to look out the mechanism responsible for the loss of UCP2 
and the reciprocal increase of UCP3 which might be unique to ccRCC.  The use 
of UCP2 inhibitor, genipin and the UCP2 expression in 786-O cells demonstrated 
the role of UCP2 in compromising mitochondrial membrane potential, suggesting 
its role in uncoupling OXPHOS. However, it remains to be elucidated if UCP2 
does increase the proton conductance which is a more direct method in 
ascertaining its uncoupling action. On the other hand, functions of UCP3 which 
was increased in the ccRCC tumor have to be examined. If UCP3 also governs the 
transport of proton, it would be interesting to study the interplay between UCP2 
and UCP3 in respect to the higher MMP in ccRCC as well as other tumors. 
 The ability of mitochondria isolated from ccRCC tumor in metabolizing 
glutamine and its derived substrates together with the compromised PDH activity 
suggested a metabolic switch towards glutaminolysis. Given that PDH is deficient 
in the ccRCC tumor, reverse TCA cycle flux would be anticipated for 
83 
 
replenishing the acetyl CoA and oxaloacetate via the action of ATP citrate lyase. 
In fact, the preferential use of reductive carboxylation for lipogenesis is 
predominant in cells grown under hypoxia (Filipp et al., 2012; Metallo et al., 
2012). Determination of the intracellular metabolites involved in the several 
pathways, namely glycolysis, TCA cycle, glutaminolysis and fatty acid synthesis 
will provide clues on the metabolic flux engaged by the ccRCC tumor. We 
demonstrated that the higher inherent MMP in mitochondria isolated from ccRCC 
could be supported by ADP and complex I, glutamine-derived respiratory 
substrates. However, if the ccRCC tumor possesses higher level of ADP than its 
normal counterpart and whether glutamine addiction changes MMP remain to be 
solved.  
The increased reliance on glutaminolysis in cancer cells has prompted the 
development of drug targeting at glutaminase. In fact, glutaminase inhibitors such 
as CB-839, BPTES (bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl 
sulfide) and compound 968 have been reported to inhibit cancer cell growth 
(Gross et al., 2014; Seltzer et al., 2010; Wang et al., 2010). In fact, a clinical trial 
involving the study the effect of CB-839 in solid tumors including renal cell 
carcinoma is undertaken by the pharmaceutical company, Calithera Biosciences, 
Inc (South San Francisco, CA, USA). Our finding on the higher inherent MMP in 






CHAPTER 6 MATERIALS AND METHODS  
6.1 Materials 
Cell cultures – Roswell Park Memorial Institute (RPMI) 1640 medium, trypsin 
and penicillin-streptomycin mixture were purchased from Gibco®, Life 
Technologies (Carlsbad, CA, USA). Sodium bicarbonate was purchased from 
Sigma Aldrich Co. Ltd (St Louis, MO, USA). Fetal bovine serum (FBS) was 
purchased from Hyclone, Thermo Scientific (Waltham, MA, USA). 
Chemicals – 5,5’,6,6’-tetrachloro 1,1, 3,3’ tetraethylbenzimidazolcarbocyanine 
iodide (JC-1), the Amplex™ Red hydrogen peroxide/peroxidase assay kit, were 
Molecular Probes Inc. (Eugene, OR, USA). Nonidet P-40 was purchased from 
Calbiochem (San Diego, CA, USA). The following were purchased from Sigma 
Aldrich Co. Ltd (St Louis, MO): ADP, ATP, 2’,7’-dichlorofluorescein diacetate, 
tetramethylrhodamine methyl ester (TMRM), carbonyl cyanide p-
trifluoromethoxyphenylhydrazone (FCCP), L-glutamic acid, L-malic acid, 
glutamine, isocitric acid, α-ketoglutarate, TMPD, ascorbic acid, horseradish 
peroxidase type VI, (298U/mg), LDH (5.3 kU/ml), PK, NAD+, NADH, DTNB, 
acetyl-coA, hydrazine, decylubiquinone, phosphoenolpyruvate (PEP), rotenone, 
malonate, antimycin A, FL-ASC Bioluminescent cell assay kit, 
phenylmethylsulfonyl fluoride (PMSF), protease inhibitor cocktail, phosphatase 
inhibitor cocktail; Tween-20 was from Sinopharm Chemical Reagent Co. Ltd 
(Shanghai, CHN). Disodium succinate hexahydrate was purchased from Merck & 
Co. (Whitehouse Station, NJ, USA). 
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Antibodies used for western blotting – mouse monoclonal anti-HIF1α and 
rabbit polyclonal anti-HIF2α were from Novus Biologicals (Littleton, CO, USA); 
MitoProfile® Total OXPHOS Rodent WB Antibody Cocktail (MS604) was from 
MitoSciences (Eugene, OR, USA); goat polyclonal anti-mtTFA, rabbit polyclonal 
anti-PGC1α and NRF-1, goat polyclonal anti-HKII, mouse monoclonal anti-KGA, 
goat polyclonal anti-UCP2 were from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA); rabbit polyclonal anti-Lactate dehydrogenase isoenzyme V (LDH-V) from 
Abcam (Cambridge, UK); rabbit monoclonal antibodies for pyruvate 
dehydrogenase kinase 1 (PDHK1) was from Cell Signaling Technology (Beverly, 
MA, USA); Manganese SOD (MnSOD) was from BD Transduction Lab 
(Franklin Lakes, NJ, USA); rabbit polyclonal antibodies for UCP2 from Alpha 
Diagnostic (San Antonio, TX, USA), UCP1 and UCP3  from CHEMICON 
International Inc. (Temecula, CA, USA); mouse monoclonal anti-PDHE1α  from 
Invitrogen (Carlsbad, CA, USA); mouse monoclonal anti-Actin, pan Ab-5  from 
NeoMarkers (Fremont, CA, USA); mouse monoclonal anti-α-tubulin from Sigma-
Aldrich (St. Louis, MO, USA). All secondary antibodies were conjugated with 
horseradish peroxidase and purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). 
6.2 Methods 
6.2.1 Human tissues from ccRCC  
Freshly resected, paired normal renal and tumor samples were collected from 18 
patients after the nephrectomy procedure in National University of Singapore 
under the approval and patients’ consent obtained from National University 
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Health Services (DSRB B/11/158). Pathological analysis confirmed that all the 
tumor samples were clear cell renal cell carcinoma of various histological grades 
except samples #8, #11 and #14 which are respectively, unclassified renal cell 
carcinoma, epithelioid angiomyolipoma and chromophobe renal cell carcinoma. 
Particulars of samples are shown in Table 1. Preparation of mitochondria was 
carried out within 1h after excision using the method described below. 
6.2.2 Isolation of intact mitochondria, mitochondrial and cytosolic fractions 
The tissues were first trimmed of fat and connective tissues and rinsed in an 
isolation buffer (at a ratio of 1g tissue to 3ml buffer) containing 2mM Tris, 
250mM sucrose, 4mM KCl, 2mM EGTA, pH 7.5. This was followed by 
homogenization by hand with a tight fitting glass–glass homogenizer using 15 up-
and-down passes. The homogenate was centrifuged at 1000g for 10min at 4°C. 
The supernatant was collected and centrifuged twice at 10,000g for 10min each 
time to obtain the mitochondrial pellet which was finally resuspended in the same 
isolation buffer. The pooled supernatant was centrifuged at 100,000g for 1h to 
obtain the cytosolic fraction which was routinely frozen at −80°C for subsequent 
assays. Protein determination was carried out by the method reported (Bradford, 
1976). 
6.2.3 Preparation of tissue lysate 
Snap-frozen tissue was kept in -80°C freezer till the day of lysate preparation. The 
tissues were thawed followed by the addition of lysis buffer (at a ratio of 1g tissue 
to 3ml buffer) containing 20mM Tric-HCl, pH7.4, 150mM NaCl, 1mM EDTA, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1mM PMSF, 1X inhibitor 
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cocktails for protease and phosphatase (both from Sigma Aldrich Co. Ltd, St 
Louis, MO, USA). The tissues were cut into small pieces and homogenized. The 
homogenate was left on ice for 2h with frequent vortexing followed by 
centrifugation at 16000g for 20min at 4°C. The supernatant was collected as 
tissue lysate and kept at -80°C freezer till use. 
6.2.4 Cell culture and genipin treatment 
786-O cells were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA), and were cultured in RPMI supplemented with 10% fetal 
bovine serum, 100 U/ml of penicillin and 100µg/ml streptomycin at 37°C and 5% 
CO2. 0.2mil cells were seeded into each well of 6-well plate and left to grow 
overnight in the CO2 incubator. On the next day, genipin (50 and 200µM) or 0.1% 
DMSO (final concentration, serves as vehicle control) prepared in the culture 
medium was added to the cells which were harvested for MMP measurement after 
3h incubation in the CO2 incubator. 
6.2.5 Preparation of whole cell lysate 
786-O cells were washed with ice-cold PBS followed by the addition of lysis 
buffer (0.5% Triton X-100, 150mM NaCl, 10mM Tris pH 7.4, 1mM EDTA, 0.5% 
NP-40, 2mM sodium orthovanadate) containing 1X protease and phosphatase 
inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). The cells were scraped 
off with a rubber policeman and vortexed for 10sec every 5min for 20min. In 
between, the cell lysate was put on ice. This was followed by centrifugation at 
14,000g for 15min at 4°C. The supernatant was collected and subjected to protein 
determination or western blot analysis.  
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6.2.6 Western blot analysis in tissue lysate or whole cell lysate 
10 to 50µg lysate were resolved on 8 to 15% sodium dodecyl sulfate-
polyacrylamide gel and electroblotted onto nitrocellulose for 1h at 4°C.  After 
blocking with 5% milk (or BSA for phospho protein) in TBST, the membranes 
were incubated with primary antibodies at a ratio of 1:1000 in 0.5% BSA for 
overnight at 4°C.  The membrane was washed and incubated with horseradish 
peroxidase-conjugated secondary antibody at 1:15000 (Santa Cruz) for 1 h at 
room temperature in 5% milk (or BSA for phospho protein) in TBS with 0.1% 
Tween-20. Detection was performed via SuperSignal West Pico or Femto 
Maximum sensitivity substrate (Pierce, Rockford, IL, USA).  
6.2.7 Enzyme activities in freeze-thawed mitochondrial extract 
6.2.7.1 Complex I (NADH dehydrogenase) activity 
Complex I activity was measured by the oxidation of NADH. The assay mixture 
contained 25mM potassium phosphate (pH 7.2), 5mM MgCl2, 0.064mM 
decylubiquinone, 2mg/ml albumin, 2mM KCN and 5mM NADH. The reaction 
was started upon addition of mitochondrial extract and the NADH fluorescence 
was followed at Ex/Em 352/464nm in a luminescence spectrophotometer (LS55, 
PerkinElmer Waltham, MA, USA). Changes in the velocity were tabulated 
according to the standard curve by adding known amount of NADH. 
 6.2.7.2 Complex V (FoF1-ATPase) activity 
ATPase activity was coupled to the reactions of lactate dehydrogenase and 
pyruvate kinase and the oxidation of NADH was followed at 340nm. The reaction 
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mixture contained 50mM Tris, pH8.0, 5mg/ml BSA, 20mM MgCl2, 50mM KCl, 
10mM phosphoenolpyruvate (PEP), 2.5mM ATP, 4 units lactate dehydrogenase, 
4 units pyruvate kinase and 1mM NADH. The reaction was started by adding the 
reaction mixture into the wells containing the enzyme extract, both of which were 
separately pre-incubated at 37°C for 5min. 
6.2.7.3 Pyruvate dehydrogenase complex (PDHc) activity 
Both active (dephosphorylated) and total (phosphorylated and dephosphorylated) 
PDHc activities were determined following the reported protocol (Eboli and 
Pasquini, 1994).  
6.2.7.4 Citrate synthase activity 
The assay was started by adding 0.5 mM oxaloacetate to a mixture containing 0.1 
mM DTNB (5, 5′-dithiobis-(2-nitrobenzoic acid), 0.3 mM acetyl CoA and an 
aliquot of mitochondrial extract containing 0.1 mg protein. The absorbance was 
followed for 5 min at 412 nm at 37 °C (Trounce et al., 1996).   
6.2.7.5 Malate dehydrogenase (MDH) activity  
The assay was started by adding 5mM malate to a mixture containing 100mM 
KH2PO4 pH7.40, 0.16% Triton X-100, 1mM NAD+ and an aliquot of 
mitochondrial extract containing 0.01mg protein. Fluorescence of NADH was 
followed at Ex/Em 352/464nm in a luminescence spectrophotometer (LS55, 
PerkinElmer Waltham, MA, USA) (Heyde and Ainsworth, 1968).  
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6.2.7.6 Glutaminase activity 
The glutaminase activity was measured by a two-step assay. 5 µl mitochondrial 
extract containing glutaminase was added to the first assay mixture containing 
20mM glutamine, 150mM KH2PO4, 0.2mM EDTA, 50mM Tris-HCL, pH8.60 in 
a final volume of 20µl. The samples were incubated for 30min at 37°C followed 
by addition of 2µl of 3M HCl to stop the reaction. 200µl of the second mixture 
containing 0.08mg/ml GDH, 80mM Tris-HCl, pH9.40, 200mM hydrazine, 
2.5mM ADP, 0.2mM NAD+ was then added. The formation of NADH was 
followed at 340nm using the absorbance microplate reader, Spectramax 190 
(Molecular Devices Corporation, Sunnyvale, CA, USA) and the initial velocity 
was used to calculate the specific enzyme activity. Blank with HCl added into the 
first mixture prior to the addition of mitochondria extract showed no activity. 
6.2.8 Mitochondrial membrane potential (MMP) of isolated mitochondria 
The MMP of freshly isolated mitochondria was examined using the specific 
mitochondrial probe, JC-1 by following its fluorescence at Ex/Em of 
485nm/535nm for the green monomer and 485nm/595nm for the red aggregate as 
described previously in our reports (Lim et al., 2011; Ng et al., 2006; Zhang et al., 
2004). 125µM ADP was added into intact mitochondria containing 0.05 to 0.2mg 
protein, followed by the respiratory substrates and inhibitors: 5mM each 
malate/glutamate (Mal/Glut), 5µM rotenone (ROT), 10mM succinate (Succ) and 
4µg/ml antimycin A (AA). For glutamine and its derived substrates, 2mM 
glutamine (Gln), 5mM glutamate (Glut), 2.5mM α-ketoglutarate (α-KG) or 5mM 
isocitrate (Iso) was added. 
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6.2.9 MMP determination of 786-O cells using TMRM and flow cytometry 
In order to measure the MMP, 786-O cells were probed with 
tetramethylrhodamine methyl ester (TMRM) which selectively accumulates in the 
mitochondria due to its positive charge. After treated with genipin or transfected 
with UCP2 vector, cells were dislodged by treatment of trypsin-EDTA. 
0.15million cells were incubated with 150µl of Hank's Balanced Salt Solution 
(HBSS) containing 1mg/ml glucose supplemented with 100nM TMRM (Sigma 
Aldrich Co. Ltd, St Louis, MO, USA) for 15min at 37°C. Positive control was 
achieved by treating the cells with 1µM FCCP and subjected to the same 
incubation conditions. After which, the TMRM-containing buffer was removed 
by centrifugation and cells were resuspended in HBSS/glucose buffer followed by 
flow cytometry analysis on a FACSCanto™ II (BD Biosciences, Franklin Lakes, 
NJ, USA). The cells were excited with an air-cooled argon 488nm laser and the 
fluorescence of TMRM was monitored in the PE channel, 10000 events per 
condition were collected for each histogram.  
 6.2.10 ATP biosynthesis 
ATP synthesis from exogenous ADP and respiratory substrates was measured in 
isolated mitochondria. Routinely, mitochondria containing 0.05mg protein were 
added to 0.5ml of buffer (100mM KCl, 12.5mM KH2PO4, 10mM Tris, pH7.60) 
containing 125 µM ADP and the following respiratory substrates ± inhibitor: 
5mM each malate/glutamate, 10mM succinate + 5µM rotenone, 5mM ascorbate 
and 1mM TMPD+2µg/ml antimycin A, 2mM glutamine, 5mM glutamate, 2.5mM 
α-ketoglutarate or 5mM isocitrate. The assay mixture was incubated for 5min at 
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37°C before ATP production was stopped by placing the tubes in boiling water 
for 3 min followed by centrifugation at 20,000g for 10min in a microfuge. The 
amount of ATP produced was determined by the luciferin/luciferase assay as 
described previously (Zhang et al., 2004) and the chemiluminescence generated 
was read in a luminometer (Victor 3, PerkinElmer Waltham, MA, USA) as 
described previously (Ng et al., 2006).  
 6.2.11 Oxygen consumption 
Mitochondrial oxygen consumption was measured using the O2K, Oroboros 
(Innsbruck, Austria). Air calibration was performed with MiR05 containing 
0.5mM EGTA, 3mM MgCl2.6H2O, 60mM K-lactobionate, 20mM Taurine, 
10mM KH2PO4, 20mM HEPES, 110mM sucrose, 1g/L BSA, pH 7.1. The 
chambers were closed after air calibration and mitochondria containing 0.05mg 
protein were added. State 4 respiration was induced by the addition of 0.5µM 
rotenone and 10mM succinate, two doses of 0.25mM ADP were added to obtain 
the State 3 respiration. A maximal capacity of the electron transport system (ETS) 
of the mitochondria was achieved by titrating sequentially with 0.1µL-1µL 
aliquots of 1mM FCCP until a maximal response was achieved as described 
(Gnaiger et al., 2000).   
6.2.12 ROS production in isolated mitochondria 
ROS production of isolation mitochondria was measured using the fluorescence 
probe, 2′,7′-dichlorofluorescin diacetate (DCFDA) which could be oxidized by 
various ROS including peroxynitrite (ONOO-), hydrogen peroxide (H2O2) in 
combination with cellular peroxidases and hydroxyl radical (·OH). The assay 
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mixture contained 0.5mg/ml mitochondria, 1U/ml horseradish peroxidase (HRP) 
and 1µM DCFDA in PBS. The fluorescence of DCF was followed at Ex/Em 
490/526nm for 30min at 37°C using the multimode microplate reader, 
Varioskan™ Flash (Thermo Scientific, West Palm Beach, FL, United States). 
6.2.13 Hydrogen peroxide production in isolated mitochondria 
H2O2 production of isolated mitochondria was measured using the Amplex Red™ 
hydrogen peroxide/peroxidase assay kit following manufacturer’s instructions. 
6.2.14 Plasmid constructs and transfection 
Myc-DDK-tagged human uncoupling protein 2 plasmid (pCMV-UCP2) was 
purchased from Origene (Rockville, MD) and validated by sequencing. The 
empty vector was created by cutting the pCMV-UCP2 vector with BamH I/Xho I 
followed by blunting the edges before ligating the ends. Subconfluent 786-O cells 
were transfected with either control or pCMV-UCP2 vector using Lipofectamine 
3000 (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Cells were harvested 24hr after transfection and used 
for MMP measurement and western blot analysis. 
6.2.15 Statistical analysis   
Data were presented as means ± SD, and were analyzed by the Student’s t test 
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